0I28.0 C$$ !0 ( !N?4 M &)C&UL4$L! A0#% @ 86E:2<(?BGEV=0 MER4& !0 ( !@R\! &)C&UL4$L! M A0#% @ 86E:26,CL@[C.P 1L0$ !0 ( !Z4! &)C H&UL4$L%!@ & 8 A $ $#A 0 $! end

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-16-747585.txt : 20161026 0001193125-16-747585.hdr.sgml : 20161026 20161026131005 ACCESSION NUMBER: 0001193125-16-747585 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161026 DATE AS OF CHANGE: 20161026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BARD C R INC /NJ/ CENTRAL INDEX KEY: 0000009892 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 221454160 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06926 FILM NUMBER: 161952076 BUSINESS ADDRESS: STREET 1: 730 CENTRAL AVE CITY: MURRAY HILL STATE: NJ ZIP: 07974 BUSINESS PHONE: 9082778000 MAIL ADDRESS: STREET 1: 730 CENTRAL AVENUE CITY: MURRAY HILL STATE: NJ ZIP: 07974 10-Q 1 d253269d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

Commission File Number 1-6926

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

New Jersey

730 Central Avenue

Murray Hill, New Jersey 07974

22-1454160

(State of incorporation)

(Address of principal

executive offices)

(I.R.S. Employer

Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Outstanding at September 30, 2016
Common Stock - $0.25 par value		73,526,324

C. R. BARD, INC. AND SUBSIDIARIES

INDEX


		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)

	Condensed Consolidated Statements of Operations for the Quarter and Nine Months Ended September 30, 2016 and 2015		3

	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Quarter and Nine Months Ended September 30, 2016 and 2015		4

	Condensed Consolidated Balance Sheets – September 30, 2016 and December 31, 2015		5

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015		6

	Notes to Condensed Consolidated Financial Statements		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		31

Item 4.	Controls and Procedures		31

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings		32

Item 1A.	Risk Factors		35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		35

Item 5.	Other Information		36

Item 6.	Exhibits		36

Signatures			37

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars in thousands except per share amounts, unaudited)


	Quarter Ended September 30,					Nine Months Ended September 30,
	2016		2015			2016		2015
Net sales	$	941,900	$	865,700		$	2,746,900	$	2,545,200

Costs and expenses:
Cost of goods sold		352,200		336,300			1,023,600		981,200
Marketing, selling and administrative expense		272,600		247,100			821,700		732,800
Research and development expense		74,200		65,200			213,800		189,800
Interest expense		14,900		11,200			39,600		33,700
Other (income) expense, net		115,800		258,300			185,400		416,300

Total costs and expenses		829,700		918,100			2,284,100		2,353,800

Income (loss) from operations before income taxes		112,200		(52,400	)		462,800		191,400

Income tax provision		15,800		33,600			91,000		192,300


Net income (loss)	$	96,400	$	(86,000	)	$	371,800	$	(900	)


Basic earnings (loss) per share available to common shareholders	$	1.30	$	(1.16	)	$	5.00	$	(0.01	)


Diluted earnings (loss) per share available to common shareholders	$	1.27	$	(1.16	)	$	4.92	$	(0.01	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(dollars in thousands, unaudited)


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net income (loss)	$	96,400		$	(86,000	)	$	371,800		$	(900	)
Other comprehensive income (loss):
Change in derivative instruments designated as cash flow hedges, net of tax		(400	)		(15,400	)		(15,900	)		(11,500	)
Foreign currency translation adjustments		(12,500	)		3,200			8,200			(61,400	)
Benefit plan adjustments, net of tax		1,700			2,000			5,100			5,800

Other comprehensive income (loss)		(11,200	)		(10,200	)		(2,600	)		(67,100	)

Comprehensive income (loss)	$	85,200		$	(96,200	)	$	369,200		$	(68,000	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except share and per share amounts, unaudited)


	September 30, 2016			December 31, 2015
ASSETS
Current assets
Cash and cash equivalents	$	996,400		$	950,500
Restricted cash		153,500			80,400
Accounts receivable, less allowances of $10,500 and $7,500, respectively		455,800			445,100
Inventories		487,700			413,700
Short-term deferred tax assets		116,100			123,900
Other current assets		92,900			79,600

Total current assets		2,302,400			2,093,200

Property, plant and equipment, at cost		866,900			807,800
Less accumulated depreciation and amortization		390,000			335,400

Net property, plant and equipment		476,900			472,400
Goodwill		1,268,800			1,140,600
Core and developed technologies, net		712,100			744,300
Other intangible assets, net		338,000			274,800
Deferred tax assets		20,800			21,800
Other assets		191,700			192,100

Total assets	$	5,310,700		$	4,939,200

LIABILITIES AND SHAREHOLDERS’ INVESTMENT
Current liabilities
Short-term borrowings and current maturities of long-term debt	$	—		$	250,200
Accounts payable		95,700			70,700
Accrued expenses		588,200			730,000
Accrued compensation and benefits		170,300			187,900
Income taxes payable		20,900			23,000

Total current liabilities		875,100			1,261,800

Long-term debt		1,641,200			1,144,100
Other long-term liabilities		960,600			936,700
Deferred income taxes		111,700			141,300
Commitments and contingencies
Shareholders’ investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued		—			—
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 73,526,324 shares at September 30, 2016 and 73,697,371 shares at December 31, 2015		18,400			18,400
Capital in excess of par value		2,314,800			2,148,400
Accumulated deficit		(400,500	)		(503,500	)
Accumulated other comprehensive loss		(210,600	)		(208,000	)

Total shareholders’ investment		1,722,100			1,455,300

Total liabilities and shareholders’ investment	$	5,310,700		$	4,939,200

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)


	Nine Months Ended September 30,
	2016			2015
Cash flows from operating activities:
Net income (loss)	$	371,800		$	(900	)
Adjustments to reconcile net income to net cash provided by operating activities, net of acquired businesses:
Depreciation and amortization		160,700			143,000
Litigation charges, net		159,200			590,000
Restructuring and productivity initiative costs, net of payments		3,800			14,600
Asset impairment		1,200			—
Deferred income taxes		(42,800	)		(32,800	)
Share-based compensation		68,300			61,100
Inventory reserves and provision for doubtful accounts		23,300			16,300
Other items		2,100			3,900
Changes in assets and liabilities, net of acquired businesses:
Accounts receivable		10,300			5,100
Inventories		(78,700	)		(38,500	)
Current liabilities		(310,400	)		(133,800	)
Taxes		(19,500	)		57,200
Other, net		(5,100	)		(3,900	)

Net cash provided by operating activities		344,200			681,300

Cash flows from investing activities:
Capital expenditures		(64,600	)		(79,300	)
Change in restricted cash		(73,100	)		(14,200	)
Payments made for purchases of businesses, net of cash acquired		(202,800	)		(74,500	)
Payments made for intangibles		(600	)		(700	)

Net cash used in investing activities		(341,100	)		(168,700	)

Cash flows from financing activities:
Change in short-term borrowings, net		—			(78,000	)
Proceeds from issuance of long-term debt, net		495,600			—
Payment of long-term debt		(250,000	)		(4,000	)
Proceeds from exercises under share-based compensation plans, net		49,800			50,600
Excess tax benefit relating to share-based compensation plans		35,300			32,000
Purchases of common stock		(231,800	)		(386,300	)
Dividends paid		(55,300	)		(51,600	)
Payments of contingent consideration		(1,700	)		(6,900	)

Net cash provided by (used in) financing activities		41,900			(444,200	)

Effect of exchange rate changes on cash and cash equivalents		900			(26,800	)

Increase in cash and cash equivalents during the period		45,900			41,600

Balance at January 1		950,500			960,100

Balance at September 30	$	996,400		$	1,001,700

Supplemental cash flow information
Cash paid for:
Interest	$	37,100		$	37,400
Income taxes		118,000			135,900
Non-cash transactions:
Purchases of businesses and related costs	$	17,100		$	5,700

The accompanying notes are an integral part of these condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2015 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2015 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarters ended August 31, 2016 and August 31, 2015 and as of November 30, 2015. No events occurred related to these foreign subsidiaries during the months of September 2016, September 2015 or December 2015 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

Recently Adopted Accounting Pronouncement

In April 2015, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires debt issuance costs to be presented as a direct deduction from the carrying amount of the related debt rather than as an asset. In 2016, the company retrospectively adopted this update, as required, and the amounts reclassified from other assets to long-term debt on the consolidated balance sheets were not material.

New Accounting Pronouncements Not Yet Adopted

In March 2016, the FASB issued an accounting standard update that includes multiple provisions intended to simplify various aspects of the accounting for share-based payments, including the income tax items and the classification of these items on the statement of cash flows. This update will be effective as of the beginning of Bard’s 2017 fiscal year. The company is assessing this update and has not yet determined the impact to the consolidated financial statements.

In February 2016, the FASB issued a new accounting standard to use in the accounting for leases. The new standard will require, among other items, lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This standard will be effective as of the beginning of Bard’s 2019 fiscal year. The company is assessing the new standard and has not yet determined the impact to the consolidated financial statements.

In November 2015, the FASB issued an accounting standard update that simplifies the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the balance sheet. This update will be effective as of the beginning of Bard’s 2017 fiscal year. Other than the reclassification to non-current of the short-term deferred tax assets and liabilities recognized in the consolidated balance sheets, this update is not expected to have a material impact on the company’s consolidated financial statements.

In May 2014, the FASB issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The company continues to assess the new standard, as well as updates to the standard that have been proposed by the FASB, and has not yet determined the impact to the consolidated financial statements. The company will adopt the new standard beginning with Bard’s 2018 fiscal year.

2. Acquisitions

On January 21, 2016, the company acquired all of the outstanding shares of Liberator Medical Holdings, Inc. (“Liberator”), a publicly-held direct-to-consumer distributor of urological catheters, ostomy supplies, mastectomy fashions and diabetic medical supplies for a purchase price of $181.1 million. This acquisition enhanced the company’s position in the home healthcare market in the United States. The acquisition was accounted for as a business combination, and the results of operations have been included in the company’s results since the acquisition date. The fair value of the assets acquired and the liabilities assumed results in the recognition of: customer relationships of $53.0 million; other intangibles of $26.0 million, primarily consisting of a trade name and non-compete agreements; deferred tax liabilities of $31.6 million, primarily associated with intangible assets; and other net assets of $11.9 million. The excess of the purchase price over fair value of the acquired net assets was recorded as goodwill of $121.8 million. The goodwill recognized includes the value of expected market expansion in the home healthcare market through Liberator’s direct-to-consumer capabilities that provide additional opportunity for market penetration. Additionally, synergies are expected to result from the alignment of sales call points

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

within the company’s sales organization. The goodwill is not deductible for tax purposes. Customer relationships and other intangible assets are being amortized over their weighted average estimated useful lives of approximately 12 years and 8 years, respectively. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available.

On December 3, 2015, the company, through a wholly-owned foreign subsidiary, acquired all of the outstanding shares of Embo Medical Limited (“Embo”), a privately-held company headquartered in Galway, Ireland, specializing in the development of peripheral embolization devices. The total purchase consideration included an up-front cash payment of $21.0 million and the fair value of future additional milestone payments of up to $22.5 million that are contingent upon specific regulatory and revenue-related milestones being achieved, which had a fair value of $16.6 million as of the acquisition date. The acquisition was recognized in the first quarter of 2016 for this foreign subsidiary. The fair value of the assets acquired and the liabilities assumed resulted in the recognition of: an acquired in-process research and development asset (“IPR&D”) of $36.1 million related to the development of the Caterpillar^TM vascular plug device; goodwill of $4.4 million; and other net liabilities of $2.9 million. The goodwill is not deductible for tax purposes. The fair value of the IPR&D asset was determined based upon the present value of expected future cash flows adjusted for the probability of technological and regulatory success, utilizing a risk-adjusted discount rate of 17.5%. The fair value of the future contingent consideration was determined utilizing a probability weighted cash flow estimate adjusted for the expected timing of the payment. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available.

3. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:


	Quarter Ended September 30,					Nine Months Ended September 30,
	2016		2015			2016		2015
(dollars and shares in millions)
EPS Numerator:
Net income (loss)	$	96.4	$	(86.0	)	$	371.8	$	(0.9	)
Less: Income allocated to participating securities		0.4		—			1.8		—

Net income (loss) available to common shareholders	$	96.0	$	(86.0	)	$	370.0	$	(0.9	)

EPS Denominator:
Weighted average common shares outstanding		74.1		74.1			74.0		74.2
Dilutive common share equivalents from share-based compensation plans		1.2		—			1.2		—

Weighted average common and common equivalent shares outstanding, assuming dilution		75.3		74.1			75.2		74.2

For both the quarter and nine months ended September 30, 2015, common share equivalents of approximately 1.3 million were not included in the computation of diluted weighted average shares outstanding. Common share equivalents primarily from share-based compensation plans were not included in these periods because their effect would have been anti-dilutive.

4. Income Taxes

The company’s effective tax rate for the quarter and nine months ended September 30, 2016 was 14.1% and 19.7%, respectively. The effective tax rate for the quarter and nine months ended September 30, 2016 reflected the discrete tax effects of litigation charges related to product liability claims, which were substantially incurred in a high tax jurisdiction and a benefit of $2.6 million related to the completion of certain U.S. Internal Revenue Service examinations. See Note 7 of the notes to condensed consolidated financial statements.

The effective tax rate for the quarter and nine months ended September 30, 2015 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction. The effective tax rate for the nine months ended September 30, 2015 also reflected the discrete tax effects of the gain related to the proceeds received from W. L. Gore & Associates, Inc. (“Gore”), which was incurred in a high tax jurisdiction. See Note 7 of the notes to condensed consolidated financial statements.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

accrued interest. At December 31, 2015, the liability for unrecognized tax benefits was $22.3 million plus $2.8 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $3.0 million within the next 12 months.

5. Financial Instruments

For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2015 Annual Report on Form 10-K.

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $321.4 million and $191.6 million at September 30, 2016 and December 31, 2015, respectively.

Interest Rate Derivative Instruments

In January 2016, the company’s outstanding interest rate swap contract was terminated concurrent with the maturity of the underlying 2.875% fixed-rate notes. The notional value of the company’s interest rate swap contract was $250 million and effectively converted these fixed-rate notes to a floating-rate instrument.

In May 2016, the company’s forward starting interest rate swap contract was settled concurrent with the issuance of 3.000% fixed-rate notes due 2026. The fair value of the forward starting interest rate swap contract at settlement recorded in accumulated other comprehensive loss was a loss of $23.3 million. This loss will be recognized as interest expense over the term of these notes. The notional value of the company’s forward swap contract was $250 million.

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:


	Balance Sheet Location		Fair Value of Derivatives
Derivatives Designated as Hedging Instruments	Balance Sheet Location		September 30, 2016		December 31, 2015
(dollars in millions)
Forward currency contracts		Other current assets	$	1.3	$	2.9
Option currency contracts		Other current assets		0.2		3.8
Interest rate swap contract		Other current assets		—		0.2
Forward currency contracts		Other assets		0.3		—

			$	1.8	$	6.9

Forward currency contracts		Accrued expenses	$	11.4	$	6.2
Interest rate swap contract		Accrued expenses		—		8.0
Forward currency contracts		Other long-term liabilities		2.5		—

			$	13.9	$	14.2

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Quarter Ended September 30,								Quarter Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(3.5	)	$	(3.6	)		Cost of goods sold	$	(1.2	)	$	(1.6	)
Option currency contracts		(0.3	)		(2.4	)		Cost of goods sold		(0.8	)		4.5
Interest rate swap contract		—			(12.9	)		Interest expense		(0.5	)		—

	$	(3.8	)	$	(18.9	)			$	(2.5	)	$	2.9


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Nine Months Ended September 30,								Nine Months Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(15.3	)	$	(5.4	)		Cost of goods sold	$	(5.9	)	$	(1.0	)
Option currency contracts		(3.3	)		8.0			Cost of goods sold		0.2			9.0
Interest rate swap contract		(15.3	)		(10.7	)		Interest expense		(0.9	)		—

	$	(33.9	)	$	(8.1	)			$	(6.6	)	$	8.0

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:


	September 30, 2016			December 31, 2015
(dollars in millions)
Forward currency contracts	$	(12.3	)	$	(3.3	)
Option currency contracts		0.2			3.8
Interest rate swap contracts		—			(7.8	)

The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to acquisitions was $19.7 million and $11.2 million at September 30, 2016 and December 31, 2015, respectively. The increase in the fair value of the liability for contingent consideration was primarily related to the addition of contingent consideration due to the acquisition of Embo and was partly offset by a reduction in the probability of the achievement of other unrelated revenue-based and manufacturing-related milestones. See Note 2 of the notes to condensed consolidated financial statements. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

Financial Instruments Not Measured at Fair Value

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2016 the company was in compliance with this covenant. There were no commercial paper borrowings outstanding at September 30, 2016 or December 31, 2015.

On May 9, 2016, the company issued $500 million aggregate principal amount of 3.000% senior unsecured notes due 2026. Interest on the notes is payable semi-annually. Net proceeds from this offering were approximately $495.6 million, after deducting debt offering costs, consisting of underwriting commissions and offering expenses of $4.3 million and a debt issuance discount of $0.1 million, which were both recorded to long-term debt. The debt offering costs and debt issuance discount will be amortized over the term of the notes. Net proceeds from the issuance of the notes were used for general corporate purposes, including repayment of outstanding commercial paper.

The estimated fair value of long-term debt (including current maturities and the effect of the related interest rate swap contract for the prior year period) was approximately $1,748.7 million and $1,449.8 million at September 30, 2016 and December 31, 2015, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation and is categorized as Level 2 under the fair value hierarchy.

The fair value of the non-contingent future payments related to the Medicon, Inc. acquisition of $79.1 million and $66.0 million at September 30, 2016 and December 31, 2015, respectively, approximated the carrying value. At September 30, 2016 and December 31, 2015, future payments of $60.3 million and $50.3 million, respectively, were recorded to other long-term liabilities. These payments will be paid in Japanese Yen and are subject to exchange rate fluctuations. The fair value was estimated by discounting the future payments based upon the timing of such payments and is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company monitors economic conditions and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries, particularly in Spain, Italy, Greece and Portugal, have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. At September 30, 2016, the company’s accounts receivable, net of allowances, from the national healthcare systems and private sector customers in these four countries was $45.9 million, of which $4.2 million was greater than 365 days past due.

6. Inventories

Inventories consisted of:


	September 30, 2016		December 31, 2015
(dollars in millions)
Finished goods	$	293.3	$	252.3
Work in process		32.9		23.8
Raw materials		161.5		137.6

	$	487.7	$	413.7

7. Contingencies

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. If the estimate of a probable loss is a range and no amount within the range is more likely, the company accrues the minimum amount of the range. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Product Liability Matters

Hernia Product Claims

As of September 30, 2016, approximately 30 federal and 80 state lawsuits involving individual claims by approximately 105 plaintiffs, as well as one putative class action in the United States, are currently pending against the company with respect to its Composix^® Kugel^® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix^® Kugel^® products beginning in December 2005. In June 2007, the Composix^® Kugel^® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL stopped accepting new cases in the second quarter of 2014. As of September 30, 2016, all but one of the putative class actions pending against the company were dismissed. The remaining putative class action pending against the company has not been certified and seeks: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2014, a settlement was reached with respect to the three putative Canadian class actions within amounts previously recorded by the company. Approximately 60 of the state lawsuits, involving individual claims by approximately 60 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products.

The company has resolved the majority of its historical Hernia Product Claims, including through agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases. Each agreement involving the settlement of a firm’s inventory of claims was subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company expects additional trials of Hernia Product Claims to take place over the next 12 months. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuit, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Women’s Health Product Claims

As of September 30, 2016, product liability lawsuits involving individual claims by approximately 10,110 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, which includes products manufactured by both the company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the company. Medtronic has an obligation to defend and indemnify the company with respect to any product defect liability. As described below, in July 2015 the company reached an agreement with Medtronic regarding certain aspects of Medtronic’s indemnification obligation. In addition, five putative class actions in the United States and five putative class actions in Canada have been filed against the company, and a limited number of other claims have been filed or asserted in various non-U.S. jurisdictions. The foregoing lawsuits, unfiled or unknown claims, putative class actions and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims”. The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2015, the Ontario Superior Court of Justice dismissed the plaintiffs’ motion for class certification in one Canadian putative class action. In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company. The company expects administration of those settlements to take place over the next several quarters.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

on December 24, 2014, which was denied on February 18, 2015. The judgment in this matter, including interest and costs, was paid on March 20, 2015 within the amounts previously recorded by the company. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million, which was upheld by the Fourth Circuit on January 14, 2016. The company does not believe that any verdicts entered to date are representative of potential outcomes of all Women’s Health Product Claims. On January 16, 2014 and July 31, 2014, the WV District Court ordered that the company prepare 200 and then an additional 300 individual cases, respectively, for trial (the “WHP Pre-Trial Orders”) (the timing for which is currently unknown). The WHP Pre-Trial Orders resulted in significant additional litigation-related defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. In February 2015, the WV District Court appointed a Special Master to assist with settlement resolution. In June 2015, the WV District Court issued an order staying the requirement to prepare a significant portion of the cases covered by the WHP Pre-Trial Orders, which stay could be modified at the court’s discretion. The WHP Pre-Trial Orders may result in material additional cost in future periods in defending Women’s Health Product Claims. The WV District Court may also order that the company prepare additional cases for trial, which could result in material additional costs in future periods.

As of September 30, 2016, the company reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 9,860 Women’s Health Product Claims, including approximately: 560 during 2014, 6,285 during 2015 and 3,015 during 2016. The company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which have not been included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Notwithstanding these settlement efforts, the company anticipates additional trials over the next 12 months. In addition, one or more possible consolidated trials may occur in the future.

In July 2015, as part of the agreement noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the company under supply agreements with Medtronic and the company has paid Medtronic $121 million towards these potential settlements. The company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreement does not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. As part of the agreement, Medtronic and the company agreed to dismiss without prejudice their previously filed litigation with respect to Medtronic’s obligation to defend and indemnify the company.

The approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 655 generic complaints involving women’s health products where the company cannot, based on the allegations in the complaints, determine whether any of those cases involve the company’s women’s health products. In addition, the approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 980 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. During the course of engaging in settlement discussions with plaintiffs’ law firms, the company has learned, and may in future periods learn, additional information regarding these and other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. While the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims and intends to vigorously defend the Women’s Health Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Filter Product Claims

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

number of lawsuits set forth above does not include approximately 40 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. The company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. The company expects that additional trials of Filter Product Claims may take place over the next 12 months. While the company intends to vigorously defend Filter Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

General

In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

The company believes that some settlements and judgments, as well as some legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the company from other parties. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. In addition, other parties may dispute their indemnification obligations to the company with respect to certain claims. When either of these occur, the company intends to vigorously contest disputes with respect to its insurance coverage or indemnification and to enforce its rights, and accordingly, will record expected recoveries with respect to amounts due under these policies or arrangements, when recovery is probable. Amounts recovered under the company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.

The company’s insurance coverage with respect to the Hernia Product Claims has been exhausted. The company continues to evaluate its available insurance coverage as it relates to Women’s Health Product Claims and Filter Product Claims.

Other Legal Matters

Since early 2013, the company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In November 2015, the Department of Defense Inspector General issued an investigative subpoena to the company. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In June 2011, Gore filed suit in the U.S. District Court in Delaware alleging the company had infringed on several of Gore’s patents. Fact and expert discovery have been completed and in the fourth quarter of 2014, the parties both filed a number of motions, including motions for summary judgment. Oral arguments on the motions occurred on January 30, 2015. In December 2015, the Delaware District Court granted the company’s summary judgment motion of no willful infringement. However, that decision was vacated in June 2016 due to a United States Supreme Court ruling that changed the test for willful infringement historically applied by the lower courts. In July 2016, the company’s summary judgment motion of laches (undue delay) was denied, at least in part because the Supreme Court will be hearing a case on this issue during the Fall 2016 term. In the third quarter of 2015, the company filed a motion to dismiss a significant portion of Gore’s damages claim on the grounds that Gore lacks proper standing. This motion was converted to a motion for summary judgment and was granted in July 2016. The trial on this matter has been set for March 2017. The company intends to vigorously defend the allegations asserted by Gore. The company cannot give any assurances that an adverse resolution of this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

Litigation Reserves

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

In the second quarter of 2014, the company recorded a charge, net of estimated recoveries to other (income) expense, net, of approximately $259 million ($238 million after tax) related to certain of the product liability matters discussed above under the heading “Product Liability Matters”. The company recorded this charge based on additional information obtained during the quarter, including but not limited to: the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Specifically, the company considered its discussions with plaintiffs’ counsel, the increase in the rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims), and the value, number of cases and nature of the inventory of cases with respect to the recent settlements of claims by the company and other manufacturers.

In the second quarter of 2015, the company recorded an additional charge related to these matters, net of estimated recoveries to other (income) expense, net, of approximately $337 million ($325 million after tax). The company recorded this charge based on additional information obtained during the quarter, including with respect to the factors noted above. Specifically the company considered the agreement and the agreement in principle by the company to settle approximately 2,880 Women’s Health Product Claims, the involvement of the Special Master in settlement resolution, additional settlements by other manufacturers subject to product liability claims with respect to similar products, and the continued rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims).

In the third quarter of 2015, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $241 million ($228 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered the agreements and the agreement in principle by the company to settle approximately 3,030 Women’s Health Product Claims, discussions with plaintiffs’ counsel, additional information learned regarding the nature and quantity of unfiled and unknown claims (which led the company to increase its estimate of future Women’s Health Product Claims), a reconciliation of claims in connection with settlements, additional settlements by other manufacturers subject to product liability claims with respect to similar products, the rate of claims being filed, and the creation of the IVC Filter MDL.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

information learned regarding the nature and quantity of unfiled and filed claims, the increase in advertising by plaintiffs’ counsel with respect to IVC filters and an increase in the rate of claims being filed in Filter Product Claims (which led the company to increase its estimate of future Filter Product Claims).

In the third quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $111 million ($77 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered, among other factors, additional information learned regarding Product Liability Matters, including regarding the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain Product Liability Matters (which led the company to increase its estimate of future claims for certain Product Liability Matters, including Filter Product Claims).

These charges recognized the estimated costs for the product liability matters discussed above, including (with respect to such matters) filed and an estimate of unfiled and unknown claims, and costs to administer the settlements related to such matters. These charges exclude any costs associated with the putative class action lawsuits in the United States.

The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including filed, unfiled and unknown claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Accruals for product liability and other legal matters amounted to $1,066.4 million, of which $404.3 million was recorded to accrued expenses, and $1,174.3 million, of which $516.5 million was recorded to accrued expenses, at September 30, 2016 and December 31, 2015, respectively. The company has made total payments of $676.5 million to qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters since 2011, of which $289.3 million were made to QSFs during the nine months ended September 30, 2016. Payments to QSFs are recorded as a component of restricted cash. Total payments of $524.8 million from these QSFs have been made to qualified claimants, of which $216.1 million were made during the nine months ended September 30, 2016. In addition, other payments of $71.6 million have been made to qualified claimants, of which $9.1 million were made during the nine months ended September 30, 2016.

The company recorded expected recoveries related to product liability matters amounting to $135.4 million, all of which was recorded to other assets, and $132.8 million, of which $132.1 million was recorded to other assets, at September 30, 2016 and December 31, 2015, respectively. The terms of the company’s agreement with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2016 and December 31, 2015 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreement. As described above, the agreement does not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. In addition, with respect to the investigative subpoenas issued by various state and federal government agencies and other legal matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual issues to be resolved. With respect to Gore’s suit against the company alleging infringement of certain of Gore’s patents, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the stage of the proceedings; (ii) the company has not received and reviewed complete information in discovery; and/or (iii) there are significant factual and legal issues to be resolved.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

8. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (the “LTIP”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. The total number of remaining shares at September 30, 2016 that may be issued under the LTIP was 4,670,191 and under the Directors’ Plan was 26,102. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs.

For the quarters ended September 30, 2016 and 2015, amounts charged against income for share-based payment arrangements were $19.0 million and $17.0 million, respectively. For the nine months ended September 30, 2016 and 2015, amounts charged against income for share-based payment arrangements were $68.3 million and $61.1 million, respectively.

In the first quarter of each of 2016 and 2015, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may exceed an officer’s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company’s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2016 and 2015 grants were estimated based on the following assumptions: risk-free interest rate of 0.83% and 0.86%, respectively; dividend yield of 0.52% and 0.51%, respectively; and expected life of 2.89 and 2.78 years, respectively.

Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) are approximately 0.1 million shares for the 2016 grant. Purchases under the MSPP were approximately 0.2 million shares for the 2015 grant. The fair value of the 2016 annual MSPP purchases was $83.23 per share and was estimated in July 2016. The fair value of the 2015 annual MSPP purchases was $60.47 per share. These fair value calculations used the Black-Scholes model based on the following assumptions: risk free interest rate of 0.39% and 0.16%, respectively; expected volatility of 18% and 17%, respectively; dividend yield of 0.5% and 0.6%, respectively; and expected life of 0.6 years for both valuations.

As of September 30, 2016, there were $109.9 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2016.

9. Pension Plans

The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

The components of net periodic pension cost are as follows:


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
(dollars in millions)
Service cost, net of employee contributions	$	7.5		$	7.1		$	22.0		$	22.1
Interest cost		4.8			5.2			14.2			15.1
Expected return on plan assets		(8.0	)		(7.9	)		(24.2	)		(23.5	)
Amortization		2.6			3.1			7.8			8.9

Net periodic pension cost	$	6.9		$	7.5		$	19.8		$	22.6

In 2016, the company changed its method used to estimate the service and interest cost components of net periodic benefit cost for defined benefit plans from a single weighted-average discount rate to a full yield curve approach. The reduction in service and interest cost for the quarter and nine months ended September 30, 2016 associated with this change in estimate was approximately $1.2 million and $3.8 million, respectively.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

10. Shareholders’ Investment

The company repurchased approximately 1.2 million shares of common stock for $231.8 million in the nine months ended September 30, 2016 under its previously announced share repurchase authorizations.

Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss) by component are as follows:


	Derivative Instruments Designated as Cash Flow Hedges			Foreign Currency Translation Adjustments			Benefit Plans			Total
(dollars in millions)
Balance at December 31, 2014	$	0.9		$	(3.1	)	$	(86.6	)	$	(88.8	)
Other comprehensive income (loss) before reclassifications		(8.3	)		(61.4	)		—			(69.7	)
Tax (provision) benefit ^(a)		2.4			—			—			2.4

Other comprehensive income (loss) before reclassifications, net of taxes		(5.9	)		(61.4	)		—			(67.3	)

Reclassifications		(8.0	)^(b)		—			8.9	^(c)		0.9
Tax provision (benefit)		2.4			—			(3.1	)		(0.7	)

Reclassifications, net of tax		(5.6	)		—			5.8			0.2

Other comprehensive income (loss)		(11.5	)		(61.4	)		5.8			(67.1	)

Balance at September 30, 2015	$	(10.6	)	$	(64.5	)	$	(80.8	)	$	(155.9	)


Balance at December 31, 2015	$	(8.7	)	$	(94.2	)	$	(105.1	)	$	(208.0	)
Other comprehensive income (loss) before reclassifications		(31.1	)		8.2			—			(22.9	)
Tax (provision) benefit ^(a)		8.5			—			—			8.5

Other comprehensive income (loss) before reclassifications, net of taxes		(22.6	)		8.2			—			(14.4	)

Reclassifications		6.6	^(b)		—			7.8	^(c)		14.4
Tax provision (benefit)		0.1			—			(2.7	)		(2.6	)

Reclassifications, net of tax		6.7			—			5.1			11.8

Other comprehensive income (loss)		(15.9	)		8.2			5.1			(2.6	)

Balance at September 30, 2016	$	(24.6	)	$	(86.0	)	$	(100.0	)	$	(210.6	)

(a)	Income taxes are not provided for foreign currency translation adjustment.

(b)	See Note 5 of the notes to condensed consolidated financial statements.

(c)	These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.

11. Segment Information

The company’s management considers its business to be a single segment entity – the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net sales based on the location of external customers by geographic region are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
United States	$	646.0	$	606.5	$	1,904.5	$	1,772.6
Europe		108.6		107.4		328.6		322.6
Japan		60.1		41.6		150.5		125.8
Other		127.2		110.2		363.3		324.2

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

Total net sales by product group category are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
Vascular	$	258.1	$	250.5	$	752.9	$	731.0
Urology		242.1		212.3		698.8		627.1
Oncology		258.4		239.3		752.7		699.1
Surgical Specialties		158.8		139.8		470.1		419.5
Other		24.5		23.8		72.4		68.5

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis provides a review of the results of operations, financial condition and the liquidity and capital resources of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”). The following discussion should be read in conjunction with Bard’s 2015 Annual Report on Form 10-K, and the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. Certain statements contained herein may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995; see “Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information” below.

Overview

The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. Outside the United States, Europe, Japan and China are the company’s largest markets, while certain emerging markets in Asia, Latin America, and Eastern Europe are the company’s fastest-growing markets. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company reports sales in four major product group categories: vascular; urology; oncology; and surgical specialties. The company also has a product group category of other products.

The company’s earnings are driven by its ability to continue to generate sales of its products and improve operating efficiency. Bard’s ability to increase sales over time depends upon its success in developing, acquiring and marketing differentiated products that meet the needs of clinicians and their patients. For the nine months ended September 30, 2016, the company’s research and development (“R&D”) expense as a percentage of net sales was 7.8%. The company also makes selective acquisitions of businesses, products and technologies, generally focusing on small-to-medium sized transactions to provide ongoing growth opportunities. In addition, the company may from time-to-time consider acquisitions of larger, established companies. The company may also periodically divest lines of business in which it is not able to reasonably attain or maintain a leadership position in the market or for other strategic reasons.

Acquisitions, Legal and Other Developments

Acquisitions

See Note 2 of the notes to condensed consolidated financial statements.

Legal Developments

In the third quarter of 2016, the company recorded an additional charge related to product liability matters to other (income) expense, net, of approximately $111 million ($77 million after tax).

In the first quarter of 2016, the company recorded an additional charge related to product liability matters to other (income) expense, net, of approximately $49 million ($31 million after tax). For more information on legal matters, see Note 7 of the notes to condensed consolidated financial statements.

Debt Issuance

corporate purposes, including repayment of outstanding commercial paper. In addition, the company’s forward starting interest rate swap was settled concurrent with the issuance of these notes. See note 5 of the notes to condensed consolidated financial statements.

Medical Device Excise Tax

Beginning in 2013, the medical device industry was required to subsidize healthcare reform in the form of a 2.3% excise tax on United States sales of most medical devices. In December 2015, as part of the Omnibus Appropriations Act, the medical device excise tax was suspended for 2016 and 2017. During the quarter and nine months ended September 30, 2015, the company recorded to marketing, selling and administrative expense an excise tax of $7.0 million and $20.1 million, respectively.

Results of Operations

Net Sales

Bard’s consolidated net sales for the quarter ended September 30, 2016 increased 9% on a reported basis (10% on a constant currency basis) compared to the same period in the prior year. Bard’s consolidated net sales for the nine months ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the same period in the prior year. Net sales “on a constant currency basis” is a non-GAAP measure and should not be viewed as a replacement of GAAP results. See “Management’s Use of Non-GAAP Measures” below. Price changes had the effect of decreasing consolidated net sales for the quarter and nine months ended September 30, 2016 by approximately 40 basis points as compared to the same periods in the prior year. The continued strength of the U.S. dollar, a trend that may continue, had the effect of decreasing consolidated net sales for the quarter and nine months ended September 30, 2016 by approximately one percentage point, as compared to the same periods in the prior year. The primary exchange rate fluctuation that impacted net sales was the movement of the Euro compared to the U.S. dollar. The impact of exchange rate fluctuations on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities.

Bard’s United States net sales of $646.0 million for the quarter ended September 30, 2016 increased 7% compared to $606.5 million in the prior year quarter. International net sales of $295.9 million for the quarter ended September 30, 2016 increased 14% on a reported basis (17% on a constant currency basis) compared to $259.2 million in the prior year quarter. Bard’s United States net sales of $1,904.5 million for the nine months ended September 30, 2016 increased 7% compared to $1,772.6 million in the prior year period. International net sales of $842.4 million for the nine months ended September 30, 2016 increased 9% on a reported basis (13% on a constant currency basis) compared to $772.6 million in the prior year period.

A summary of net sales by product group category is as follows:

Product Group Summary of Net Sales


	Quarter Ended September 30,										Nine Months Ended September 30,
	2016		2015		Change			Constant Currency			2016		2015		Change			Constant Currency
(dollars in millions)
Vascular	$	258.1	$	250.5		3	%		4	%	$	752.9	$	731.0		3	%		4	%
Urology		242.1		212.3		14	%		15	%		698.8		627.1		11	%		13	%
Oncology		258.4		239.3		8	%		9	%		752.7		699.1		8	%		9	%
Surgical Specialties		158.8		139.8		14	%		14	%		470.1		419.5		12	%		13	%
Other		24.5		23.8		3	%		6	%		72.4		68.5		6	%		8	%

Total net sales	$	941.9	$	865.7		9	%		10	%	$	2,746.9	$	2,545.2		8	%		9	%

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products and vascular graft products. Also included within vascular products are royalty payments from W. L. Gore & Associates, Inc. (“Gore”). Consolidated net sales of vascular products for both the quarter and nine months ended September 30, 2016 increased 3% on a reported basis (4% on a constant currency basis) compared to the prior year periods. These increases were primarily due to growth in sales of endovascular products and were partially offset by declines in sales of divested electrophysiology products. United States net sales of vascular products for the quarter ended September 30, 2016 were flat compared to the prior year quarter. International net sales of vascular products for the quarter ended September 30, 2016 increased 9% on a reported basis (11% on a constant currency basis) compared to the prior year quarter. United States net sales of vascular products for the nine months ended September 30, 2016 increased 1% compared to the prior year period. International net sales of vascular products for the nine months ended September 30, 2016 increased 7% on a reported basis (10% on a constant currency basis) compared to the prior year period.

Consolidated net sales of endovascular products for both the quarter and nine months ended September 30, 2016 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year periods. Net sales in this product line for both the quarter and nine months ended September 30, 2016 were favorably impacted by growth in sales of percutaneous transluminal angioplasty (“PTA”) balloon catheters, including drug-coated PTA balloon catheters, and biopsy products and were partially offset by declines in sales of vena cava filters, a trend that is expected to continue.

Consolidated net sales of vascular graft products for the quarter ended September 30, 2016 decreased 1% on a reported basis (flat on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular graft products for the nine months ended September 30, 2016 increased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period.

Urology Products - Bard markets a wide range of products for the urology market, including basic urology drainage products, fecal and urinary continence products and urological specialty products. Bard also markets StatLock^® catheter stabilization products, which are used to secure many types of catheters sold by Bard and other companies, as well as Targeted Temperature Management^™ products, which are used for therapeutic hypothermia. Consolidated net sales of urology products for the quarter ended September 30, 2016 increased 14% on a reported basis (15% on a constant currency basis) compared to the prior year quarter. This increase includes 9 percentage points of growth on both a reported basis and constant currency basis from direct-to-consumer sales as a result of the Liberator acquisition in January 2016. Consolidated net sales of urology products also includes 2 percentage points of growth on both a reported basis and constant currency basis due to the impact of the Medicon, Inc. (“Medicon”) acquisition. Consolidated net sales of urology products for the nine months ended September 30, 2016 increased 11% on a reported basis (13% on a constant currency basis) compared to the prior year period, which includes 8 percentage points of growth on a reported basis (9 percentage points on a constant currency basis) as a result of the Liberator acquisition. In addition, consolidated net sales of urology products for the nine months ended September 30, 2016 includes a decline of 1 percentage point on a reported basis (flat on a constant currency basis) primarily due to the impact of the Medicon acquisition, including the sale of acquired inventory previously recorded as sales into the joint venture. Net sales for the quarter and nine months ended September 30, 2016 were also favorably impacted by growth in sales of basic drainage products and Targeted Temperature Management^™ products. For the nine months ended September 30, 2016, these increases were partially offset by a decline in sales of StatLock^® catheter stabilization products. United States net sales of urology products for the quarter ended September 30, 2016 increased 15% compared to the prior year quarter. International net sales of urology products for the quarter ended September 30, 2016 increased 11% on a reported basis (15% on a constant currency basis) compared to the prior year quarter. United States net sales of urology products for the nine months ended September 30, 2016 increased 16% compared to the prior year period. International net sales of urology products for the nine months ended September 30, 2016 increased 3% on a reported basis (6% on a constant currency basis) compared to the prior year period. International net sales for the quarter ended September 30, 2016 reflected increases in basic drainage products and urological specialty products, both primarily due to the Medicon acquisition. International net sales for the nine months ended September 30, 2016 reflected an increase in urological specialty products, due to the impact of the Medicon acquisition.

Consolidated net sales of basic drainage products for the quarter ended September 30, 2016 increased 18% on a reported basis (19% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of basic drainage products for the nine months ended September 30, 2016 increased 13% on a reported basis (14% on a constant currency basis) compared to the prior year period. The increase for the quarter ended September 30, 2016 was primarily due to sales as a result of the Liberator and Medicon acquisitions. For the nine months ended September 30, 2016, the increase was primarily due to the Liberator acquisition and was partially offset by the impact of the Medicon acquisition.

Consolidated net sales of urological specialty products for the quarter ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of urological specialty products for the nine months ended September 30, 2016 increased 7% on a reported basis (9% on a constant currency basis) compared to the prior year period. These increases were primarily due to the impact of the Medicon acquisition.

Consolidated net sales of continence products for the quarter ended September 30, 2016 increased 24% on a reported basis (28% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of continence products for the nine months ended September 30, 2016 increased 22% on a reported basis (25% on a constant currency basis) compared to the prior year period. These increases were primarily due to sales as a result of the Liberator acquisition. These increases were partially offset by a decline in sales of surgical continence products, a trend that is expected to continue.

Consolidated net sales of the StatLock^® catheter stabilization product line for the quarter ended September 30, 2016 increased 1% on a reported basis (2% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of the StatLock^® catheter stabilization product line for the nine months ended September 30, 2016 decreased 4% on a reported basis (3% on a constant currency basis) compared to the prior year period, a trend that may continue.

Oncology Products - Bard’s oncology business includes specialty vascular access products and enteral feeding devices. Specialty vascular access products include peripherally inserted central catheters (“PICCs”) used for intermediate to long-term central venous access, specialty access ports and accessories (“Ports”) used most commonly for chemotherapy, dialysis access catheters and vascular access ultrasound devices, which help facilitate the placement of PICCs. Consolidated net sales of oncology products for the quarter ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of oncology products for the nine months ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year period. These increases were primarily due to growth in sales of PICCs and Ports. United States net sales of oncology products for the quarter ended September 30, 2016 increased 3% compared to the prior year quarter. International net sales of oncology products for the quarter ended September 30, 2016 increased 19% on a reported basis (22% on a constant currency basis) compared to the prior year quarter. United States net sales of oncology products for the nine months ended September 30, 2016 increased 5% compared to the prior year period. International net sales of oncology products for the nine months ended September 30, 2016 increased 16% on a reported basis (20% on a constant currency basis) compared to the prior year period.

Consolidated net sales of PICCs for the quarter ended September 30, 2016 increased 7% on a reported basis (8% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of PICCs for the nine months ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year period.

Consolidated net sales of Ports for the quarter ended September 30, 2016 increased 9% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of Ports for the nine months ended September 30, 2016 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year period.

Consolidated net sales of dialysis access catheters for the quarter ended September 30, 2016 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of dialysis access catheters for the nine months ended September 30, 2016 increased 9% on a reported basis (11% on a constant currency basis) compared to the prior year period. Consolidated net sales of vascular access ultrasound devices for the quarter ended September 30, 2016 increased 7% on a reported basis (8% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular access ultrasound devices for the nine months ended September 30, 2016 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year period.

Surgical Specialty Products - Surgical specialty products include soft tissue repair products, performance irrigation devices and biosurgery products, including hemostats and sealants. Consolidated net sales of surgical specialty products for the quarter ended September 30, 2016 increased 14% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of surgical specialty products for the nine months ended September 30, 2016 increased 12% on a reported basis (13% on a constant currency basis) compared to the prior year period. These increases were primarily due to growth in sales of synthetic hernia repair products and biosurgery products and were partially offset by declines in sales of natural hernia repair products and performance irrigation products. United States net sales of surgical specialty products for both the quarter and nine months ended September 30, 2016 increased 11% compared to the prior year periods. International net sales of surgical specialty products for the quarter ended September 30, 2016 increased 25% on a reported basis (28% on a constant currency basis) compared to the prior year quarter. International net sales of surgical specialty products for the nine months ended September 30, 2016 increased 15% on a reported basis (19% on a constant currency basis) compared to the prior year period.

The soft tissue repair product line includes synthetic and natural tissue hernia repair implants, natural tissue breast reconstruction implants and hernia fixation products. Consolidated net sales of soft tissue repair products for the quarter ended September 30, 2016 increased 13% on a reported basis (14% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of soft tissue repair products for the nine months ended September 30, 2016 increased 12% on a reported basis (13% on a constant currency basis) compared to the prior year period.Net sales in this product line were favorably impacted by growth in sales of synthetic hernia repair products and hernia fixation products and were partially offset by declines in sales of natural tissue hernia repair products, a trend that may continue.

Consolidated net sales of biosurgery products for the quarter ended September 30, 2016 increased 21% on a reported basis (22% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of biosurgery products for the nine months ended September 30, 2016 increased 19% on both a reported basis and constant currency basis compared to the prior year period. Net sales in the product line were favorably impacted by growth in sales of hemostats.

Consolidated net sales of performance irrigation products for the quarter ended September 30, 2016 decreased 6% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of performance irrigation products for the nine months ended September 30, 2016 decreased 5% on both a reported basis and constant currency basis compared to the prior year period, a trend that may continue.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ products.

Costs and Expenses

A summary of costs and expenses as a percentage of net sales is as follows:


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015^(A)			2016^(A)			2015^(A)
Cost of goods sold		37.4	%		38.8	%		37.3	%		38.6	%
Marketing, selling and administrative expense		28.9	%		28.5	%		29.9	%		28.8	%
Research and development expense		7.9	%		7.5	%		7.8	%		7.5	%
Interest expense		1.6	%		1.3	%		1.4	%		1.3	%
Other (income) expense, net		12.3	%		29.8	%		6.7	%		16.4	%

Total costs and expenses		88.1	%		106.1	%		83.2	%		92.5	%

^(A)	Amounts do not add due to rounding.

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products. The category also includes royalties paid by the company, amortization of intangible assets and the impact of certain hedging activities. Cost of goods sold as a percentage of net sales for the quarter and nine months ended September 30, 2016 decreased 140 basis points and 130 basis points, respectively, primarily due to cost improvements. Cost of goods sold for the nine months ended September 30, 2016 included the recognition of previously deferred profit on product shipments to the joint venture prior to the Medicon acquisition, the net effect of the reversal of liabilities with respect to certain revenue-based and regulatory-related milestones, and an asset impairment. In addition, cost of goods sold for the nine months ended September 30, 2015 included the reversal of a liability with respect to a certain revenue-based milestone. Incremental amortization of intangible assets primarily related to the acquisitions of Liberator, Vascular Pathways, Inc. and Medicon increased cost of goods sold as a percentage of net sales by approximately 40 basis points and 50 basis points over the prior year quarter and nine month period, respectively.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. These costs as a percentage of net sales for the quarter and nine months ended September 30, 2016 increased 40 basis points and 110 basis points, respectively, compared to the prior year periods primarily due to related costs from operations acquired in 2015 and 2016. These increases were partially offset by the suspension of the excise tax on medical device sales for 2016.

Research and development expense - Research and development expense consists principally of costs related to internal research and development activities, third-party research and development activities, and acquired in-process R&D (“IPR&D”) arising from the company’s business development activities. IPR&D costs may impact the comparability of the company’s results of operations between periods. Research and development expense for the quarter ended September 30, 2016 was $74.2 million, an increase of approximately 14% compared to the prior year quarter. Research and development expense for the nine months ended September 30, 2016 was $213.8 million, an increase of approximately 13% compared to the prior year period.

Interest expense - Interest expense was $14.9 million and $11.2 million for the quarters ended September 30, 2016 and 2015, respectively. Interest expense was $39.6 million and $33.7 million for the nine months ended September 30, 2016 and 2015, respectively. The increase in interest expense for both the quarter and nine months ended September 30, 2016 is primarily due to the issuance of 3.000% fixed-rate notes due 2026 and amortization of the loss on the forward-starting interest rate swap.

Other (income) expense, net - The components of other (income) expense, net, are as follows:


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
(dollars in millions)
Interest income	$	(0.4	)	$	(0.3	)	$	(1.1	)	$	(0.7	)
Foreign exchange losses (gains)		0.9			5.7			(3.0	)		6.8
Litigation charges, net		110.6			241.1			159.5			595.1
Gore Proceeds		—			—			—			(210.5	)
Restructuring and productivity initiative costs		4.6			14.6			26.3			27.0
Acquisition-related items		0.2			0.8			4.1			1.3
Other, net		(0.1	)		(3.6	)		(0.4	)		(2.7	)

Total other (income) expense, net	$	115.8		$	258.3		$	185.4		$	416.3

Litigation charges, net – For the quarters ended September 30, 2016 and 2015 and the nine months ended September 30, 2016, the amounts reflect the estimated costs for product liability matters. For the nine months ended September 30, 2015, the amount reflects the estimated costs for product liability matters, net of recoveries, and litigation-related defense costs of $15.1 million in connection with the United States District Court for the Southern District of West Virginia’s pre-trial orders to prepare 500 individual cases, and certain other litigation-related charges. See Note 7 of the notes to condensed consolidated financial statements.

Gore Proceeds – For the nine months ended September 30, 2015, Gore paid the company $210.5 million, representing the total amount of the enhanced damages awarded by the U.S. District Court for the District of Arizona due to Gore’s willfulness in connection with the company’s lawsuit against Gore for infringing Bard’s patent number 6,436,135 and an audit adjustment related to the payment of royalties through September 30, 2013 (the “Gore Proceeds”). For further discussion regarding the company’s lawsuit against Gore, see Note 10 of the notes to consolidated financial statements in Bard’s 2015 Annual Report on Form 10-K.

Restructuring and productivity initiative costs – For the quarters and nine months ended September 30, 2016 and 2015, the amounts primarily reflect costs incurred in connection with productivity initiatives to optimize and streamline certain manufacturing and administrative functions to better align resources to the company’s business strategies. Key activities under these initiatives may include systems enhancements, the implementation of shared services centers designed to standardize and centralize processes or the outsourcing of certain services. Productivity initiative costs include consulting costs, primarily related to program creation and management, employee separation costs under the company’s existing severance program, and other related costs. For the quarter and nine months ended September 30, 2015, employee separation costs of $8.5 million and $10.1 million, respectively, were recognized related to these initiatives.

Acquisition-related items – For the quarters and nine months ended September 30, 2016 and 2015, the amounts primarily consist of acquisition-related integration costs.

Income Tax Provision

The company’s effective tax rate for the quarter and nine months ended September 30, 2016 was 14.1% and 19.7%, respectively. The effective tax rate for the quarter and nine months ended September 30, 2016 reflected the discrete tax effects of litigation charges related to product liability claims, which were substantially incurred in a high tax jurisdiction and a benefit of $2.6 million related to the completion of certain U.S. Internal Revenue Service (“IRS”) examinations. See Note 7 of the notes to condensed consolidated financial statements.

The effective tax rate for the quarter and nine months ended September 30, 2015 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction. The effective tax rate for the nine months ended September 30, 2015 also reflected the discrete tax effects of the gain related to the proceeds received from Gore, which was incurred in a high tax jurisdiction. See Note 7 of the notes to condensed consolidated financial statements.

Net Income (Loss) and Earnings (Loss) Per Share Available to Common Shareholders

The company reported net income and diluted earnings per share available to common shareholders for the quarter ended September 30, 2016 of $96.4 million and $1.27, respectively. Net loss and diluted loss per share available to common shareholders for the prior year quarter were $86.0 million and $1.16, respectively. The current year quarter reflects litigation charges of $77.5 million, or $1.02 per diluted share, amortization of intangible assets of $21.6 million, or $0.29 per diluted share, charges from acquisition-related items (primarily consisting of integration costs) of $3.5 million, or $0.05 per diluted

share, and restructuring and productivity initiative costs of $3.1 million, or $0.04 per diluted share. The current year quarter also reflects a $2.6 million, or $0.03 per diluted share, benefit to the income tax provision as a result of the completion of certain IRS examinations. The prior year quarter reflects litigation charges of $228.2 million, or $2.98 per diluted share, amortization of intangible assets of $20.2 million, or $0.26 per diluted share, restructuring and productivity initiative costs of $10.4 million, or $0.14 per diluted share, and net charges from acquisition-related items (primarily consisting of integration costs) of $1.9 million, or $0.03 per diluted share.

The company reported net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2016 of $371.8 million and $4.92, respectively. Net loss and diluted loss per share available to common shareholders for the prior year period were $0.9 million and $0.01, respectively. The current year nine month period reflects litigation charges of $108.3 million, or $1.43 per diluted share, amortization of intangible assets of $64.7 million, or $0.86 per diluted share, restructuring and productivity initiative costs of $17.5 million, or $0.23 per diluted share, net charges from acquisition-related items (primarily consisting of integration costs, purchase accounting adjustments and transaction costs) of $7.8 million, or $0.10 per diluted share, and an asset impairment of $1.2 million, or $0.02 per diluted share. The current year nine month period also reflects a $2.6 million, or $0.03 per diluted share, benefit to the income tax provision as a result of the completion of certain IRS examinations. The prior year nine month period reflects litigation charges, net, of $568.8 million, or $7.42 per diluted share, Gore Proceeds of $131.7 million, or $1.72 per diluted share, amortization of intangible assets of $58.8 million, or $0.77 per diluted share, restructuring and productivity initiative costs of $18.5 million, or $0.24 per diluted share, and a net benefit from acquisition-related items (primarily consisting of purchase accounting adjustments, integration costs and transaction costs) of $3.5 million, or $0.05 per diluted share.

Liquidity and Capital Resources

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and technologies, cash dividends and common stock repurchases. Cash provided from operations continues to be a primary source of funds. The company believes that it could borrow adequate funds at competitive terms should it be necessary. The company also believes that its overall financial strength gives it sufficient financial flexibility. A summary of certain liquidity measures for the company as of September 30, is as follows:


	2016		2015
(dollars in millions)
Working capital	$	1,427.3	$	806.6

Current ratio		2.63/1		1.62/1

Cash and cash equivalents held by the company’s foreign subsidiaries were $978.1 million and $881.6 million at September 30, 2016 and December 31, 2015, respectively. It is the company’s intention to permanently reinvest the majority of these funds outside the United States to finance foreign operations, and the company’s plans do not demonstrate a need to repatriate these funds. If these funds are needed for U.S. operations for currently unforeseen circumstances or can no longer be permanently reinvested outside the United States, the company would be required to accrue and pay U.S. taxes on the earnings associated with these funds. In the United States, ongoing operating cash flows and available borrowings under the company’s committed syndicated bank credit facility provide it with sufficient liquidity.

For the nine months ended September 30, 2016 and 2015, net cash provided by operating activities was $344.2 million and $681.3 million, respectively. The decrease in net cash provided by operating activities is primarily due to higher payments to claimants for certain product liability matters in the current year period and the receipt of the Gore Proceeds in the prior year period.

For the nine months ended September 30, 2016 and 2015, net cash used by investing activities was $341.1 million and $168.7 million, respectively. Capital expenditures were approximately $64.6 million and $79.3 million for the nine months ended September 30, 2016 and 2015, respectively. The company spent $203.4 million and $75.2 million for the acquisition of businesses, products and technology to augment existing product lines for the nine months ended September 30, 2016 and 2015, respectively. The current year reflects an increase of $73.1 million in restricted cash primarily related to payments to qualified settlement funds for certain product liability matters. The prior year reflects an increase of $14.2 million in restricted cash primarily related to payments to qualified settlement funds for certain product liability matters.

For the nine months ended September 30, 2016, net cash provided by financing activities was $41.9 million compared to the $444.2 million used for financing activities for the nine months ended September 30, 2015. Total debt was $1.6 billion and $1.4 billion (including current maturities of $250.2 million) at September 30, 2016 and December 31, 2015, respectively. Total debt to total capitalization was 48.8% and 48.9% at September 30, 2016 and December 31, 2015, respectively, which reflects the redemption of the $250 million 2.875% fixed-rate notes due January 2016 and net proceeds of $495.6 million

from the issuance of 3.000% fixed-rate notes due 2026. Net cash used in financing activities also reflects $231.8 million used to repurchase 1,190,004 shares of common stock in the nine months ended September 30, 2016 compared to $386.3 million to repurchase 2,145,289 shares of common stock in the prior year period. The company paid cash dividends of $0.74 per share and $0.68 per share for the nine months ended September 30, 2016 and 2015, respectively.

The company maintains a $1.0 billion five-year committed syndicated bank credit facility that expires in November 2020. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2016, the company was in compliance with this covenant. There were no commercial paper borrowings outstanding at September 30, 2016 and December 31, 2015.

Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, contractual disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. See Note 7 of the notes to condensed consolidated financial statements.

Certain Regulatory Matters

In October 2014 and November 2014, the United States Food and Drug Administration (“FDA”) conducted directed inspections at two of the company’s facilities after which the FDA issued Form-483’s to the company in connection with these inspections. The company responded to the FDA and implemented corrective and preventive actions to address the FDA’s concerns. On July 14, 2015, the company received a Warning Letter from the Los Angeles District office of the FDA. The Warning Letter specifically cites quality systems and medical device reporting observations relating to non-conformances previously identified in the Form-483 notices for Glens Falls, New York and Tempe, Arizona and appropriate market clearance or approval of two models of our Recovery Cone Removal Systems used to retrieve certain implanted filters. The Warning Letter states that, until the company resolves the outstanding issues covered by the Warning Letter, no premarket submissions for Class III devices to which the non-conformances are reasonably related will be cleared or approved. The company presently has two such submissions before the FDA, which the company does not believe are material to its business. The company implemented corrective and preventive actions to address the concerns identified in the Warning Letter and on February 18, 2016, received market clearance for the two models of the Recovery Cone Removal Systems. The FDA conducted planned follow-up inspections at the Glens Falls and Tempe facilities during the first quarter of 2016 which resulted in the FDA issuing Form-483’s identifying observations regarding the quality systems at these facilities. The company has responded to the FDA and implemented corrective and preventive actions to address the observations. In May 2016, the FDA notified the company that the FDA will require further follow-up re-inspections with respect to the issues cited in the Warning Letter.

In the second quarter of 2016, the FDA conducted an inspection at another of the company’s facilities after which the FDA issued a Form-483 to the company in connection with this inspection. The company responded to the FDA, is in the process of addressing the observations in the Form-483, and intends to fully implement corrective and preventive actions to address the FDA’s concerns.

The company cannot give any assurances that the FDA will be satisfied with its response to the Warning Letter or the Form-483’s or to the expected date of resolution of matters included in the Warning Letter or the Form-483’s. Although the company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the company’s business, results of operations, financial conditions and/or liquidity, the company does not at this time believe this will have a material impact on its financial statements.

Management’s Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in Bard’s 2015 Annual Report on Form 10-K. There have been no significant changes to the company’s critical accounting policies since December 31, 2015.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of life-sustaining medical devices. These devices are often used on, or permanently or temporarily implanted in, patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, warning letters, recalls, field corrections or regulatory enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, results of operations, financial condition and/or liquidity. For further discussion of risks applicable to our business, see “Risk Factors” in Bard’s 2015 Annual Report on Form 10-K.

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties, but the most significant factors, in addition to those addressed above and those described under Item 1A. “Risk Factors” in Bard’s 2015 Annual Report on Form 10-K, that could adversely affect our business or cause the actual results to differ materially from those expressed or implied include, but are not limited to:

Effective management of and reaction to risks involved in our business, including:

•

the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing processes and supply chain programs or in connection with the integration of acquired businesses;

•

the effects of negative publicity and/or adverse media coverage concerning our products, competitors’ products, the product or geographic markets in which we compete or our industry in general, which could result in product withdrawals, decreased product demand or adverse reputational effects and which could reduce market or governmental acceptance of our products;

•

the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and successfully integrate such transactions or to obtain agreements for such transactions on favorable terms;

•

the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

•

the ability to implement, and realize the benefits of, our prior and planned investments in our business, including research and development expenditures focused on new market categories, and our plan to grow in emerging and/or faster-growing markets outside the United States and acquire growth platforms designed to change the mix of our portfolio towards faster, sustainable long-term growth;

•

the uncertainty of whether research and development expenditures and sales force expansion will result in increased sales;

•

the ability to reduce exposure and uncertainty related to tax audits, appeals and litigation;

•

the risk that the company may not successfully implement its expansion of its Enterprise Resource Planning (“ERP”) information system and other productivity initiatives, including outsourcing certain information technology system functions;

•

internal factors, such as retention of key employees, including sales force employees;

•

the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others, and projected royalty revenue from Gore;

•

changes in factors and assumptions or actual results that differ from our assumptions on stock valuation and employee stock option exercise patterns, which could cause compensation expense recorded in future periods to differ significantly from the compensation expense recorded in the current period;

•

changes in factors and assumptions could cause pension cost recorded in future periods to differ from the pension cost recorded in the current period;

•

the effect of market fluctuations on the value of assets in the company’s pension plans and the possibility that the company may need to make additional contributions to the plans as a result of any decline in the fair value of such assets;

•

damage to a facility where our products are manufactured or from which they are distributed, which could render the company unable to manufacture or distribute one or more products and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets;

•

the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets;

•

the ability to obtain appropriate levels of insurance on reasonable terms, or at all;

•

the ability to recover for claims made to our insurance companies or under indemnification obligations to the company and that any amounts recovered under these arrangements may not be adequate to cover the company’s damages and/or costs; and

•

the ability to realize the anticipated benefits of our restructuring activities and productivity initiatives to improve the company’s overall cost structure and improve efficiency.

Competitive factors, including:

•

the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures, competition and more significant and complex contracts than in the past, both in the United States and abroad;

•

development of new products or technologies by competitors having superior performance compared to our current products or products under development which could negatively impact sales of our products or render one or more of our products obsolete;

•

technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

•

attempts by competitors to gain market share through aggressive marketing programs; and

•

reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

•

the ability to complete planned and/or ongoing clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

•

lengthy and costly regulatory approval processes, which may result in lost market opportunities and/or delayed product launches;

•

delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

•

the suspension or revocation of authority to manufacture, market or distribute existing products;

•

the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

•

performance, efficacy, quality or safety concerns for existing products, whether scientifically justified or not, that may lead to product discontinuations, product withdrawals, recalls, field corrections, regulatory enforcement actions, litigation or declining sales, including adverse events and/or concerns relating to the company’s vena cava filters, pelvic floor repair products and hernia repair products;

•

FDA inspections resulting in Form-483 notices and/or warning letters identifying deficiencies in the company’s manufacturing practices and/or quality systems; warning letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA and/or civil penalties; uncertainty regarding the expected date of resolution of any of these matters;

•

the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

•

difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials, including oil-based resins, or other interruptions of the supply chain; and

•

customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organizations.

Governmental action, including:

•

the impact of continued healthcare cost containment;

•

new laws and judicial decisions related to healthcare availability, healthcare reform, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce or eliminate reimbursements for procedures that use the company’s products;

•

changes in the FDA and/or foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

•

the impact of compliance and enforcement activities affecting the healthcare industry in general or the company in particular (including sales and marketing practices);

•

changes in tax laws affecting our business, such as the potential for comprehensive tax reform in the United States and proposed legislation in multiple jurisdictions resulting from the adoption of Organisation for Economic Co-operation and Development (OECD) policies;

•

changes in environmental laws or standards affecting our business including, among others, compliance with new labeling standards related to ozone-depleting substances;

•

changes in laws that could require facility upgrades or process changes and could affect production rates and output; and

•

compliance costs and potential penalties and remediation obligations in connection with environmental laws, including regulations regarding air emissions, waste water discharges and solid waste.

Legal disputes, including:

•

disputes over legal proceedings, the outcome and the timing of final resolution of the suit filed by Gore against the company;

•

product liability claims, which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims;

•

claims asserting securities law violations;

•

claims asserting, and/or subpoenas seeking information regarding, violations of law in connection with federal and/or state healthcare programs such as Medicare or Medicaid;

•

derivative shareholder actions;

•

claims and subpoenas asserting antitrust violations;

•

environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

•

commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements, development/research agreements (including indemnification provisions), acquisition or sale agreements, and insurance policies.

General economic conditions, including:

•

international and domestic business conditions;

•

political or economic instability in foreign countries;

•

interest rates;

•

foreign currency exchange rates;

•

changes in the rate of inflation;

•

instability of global financial markets and economies including Greece, Italy, Spain, Portugal and certain other countries or places where we operate or do business; and

•

The United Kingdom’s vote to depart the European Union.

Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, strikes, work stoppages or slowdowns, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The quantitative and qualitative disclosures about market risk are discussed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in Bard’s 2015 Annual Report on Form 10-K. There have been no material changes in the information reported since the year ended December 31, 2015.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of September 30, 2016. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2016, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to accomplish their objectives at the reasonable assurance level. The scope of management’s assessment of the effectiveness of the design and operation of the company’s disclosure controls and procedures as of September 30, 2016 includes all of the company’s consolidated operations except for those disclosure controls and procedures of Liberator Medical, Inc. and Medicon, Inc. that are subsumed by internal control over financial reporting. The company acquired Liberator Medical, Inc. on January 21, 2016 and Medicon, Inc. on November 2, 2015. The operations related to these acquisitions represent 8.6% of the company’s consolidated net sales for the quarter ended September 30, 2016 and assets associated with the operations related to these acquisitions represent 4.2% of the company’s consolidated total assets as of September 30, 2016. In the second quarter of 2016, there were changes in the company’s internal control over financial reporting related to the transition to an outsourcing service provider of certain information technology functions that had been performed internally. The transition of these functions has resulted in changes in certain information technology infrastructure and application maintenance from internally performed to externally performed by the outsourcing service provider. There have been no changes in the company’s internal control over financial reporting during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, the company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

Hernia Product Claims

Women’s Health Product Claims

in one Canadian putative class action. In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company. The company expects administration of those settlements to take place over the next several quarters.

In October 2010, the Women’s Health Product Claims involving solely Avaulta^® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia (the “WV District Court”), the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The first trial in a state court was completed in California in July 2012 and resulted in a judgment against the company of approximately $3.6 million. On appeal the decision was affirmed by the appellate court in November 2014. The company filed a petition for review to the California Supreme Court on December 24, 2014, which was denied on February 18, 2015. The judgment in this matter, including interest and costs, was paid on March 20, 2015 within the amounts previously recorded by the company. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million, which was upheld by the Fourth Circuit on January 14, 2016. The company does not believe that any verdicts entered to date are representative of potential outcomes of all Women’s Health Product Claims. On January 16, 2014 and July 31, 2014, the WV District Court ordered that the company prepare 200 and then an additional 300 individual cases, respectively, for trial (the “WHP Pre-Trial Orders”) (the timing for which is currently unknown). The WHP Pre-Trial Orders resulted in significant additional litigation-related defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. In February 2015, the WV District Court appointed a Special Master to assist with settlement resolution. In June 2015, the WV District Court issued an order staying the requirement to prepare a significant portion of the cases covered by the WHP Pre-Trial Orders, which stay could be modified at the court’s discretion. The WHP Pre-Trial Orders may result in material additional cost in future periods in defending Women’s Health Product Claims. The WV District Court may also order that the company prepare additional cases for trial, which could result in material additional costs in future periods.

Filter Product Claims

As of September 30, 2016, product liability lawsuits involving individual claims by approximately 1,055 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products (all lawsuits, collectively, the “Filter Product Claims”). In August 2015, the Judicial Panel for Multi-District Litigation (“JPML”) ordered the creation of a Multi-District Litigation for all federal Filter Product Claims (the “IVC Filter MDL”) in the District of Arizona. There are approximately 1,005 Filter Product Claims that have been, or shortly will be, transferred to the IVC Filter MDL. The remaining approximately 50 Filter Product Claims are pending in various state courts. In March 2016, a Canadian class action was filed against the company in Quebec. In April 2016 and May 2016, Canadian class actions were filed in Ontario and British Columbia, respectively. The approximate number of lawsuits set forth above does not include approximately 40 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. The company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. The company expects that additional trials of Filter Product Claims may take place over the next 12 months. While the company intends to vigorously defend Filter Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

General

Other Legal Matters

laches (undue delay) was denied, at least in part because the Supreme Court will be hearing a case on this issue during the Fall 2016 term. In the third quarter of 2015, the company filed a motion to dismiss a significant portion of Gore’s damages claim on the grounds that Gore lacks proper standing. This motion was converted to a motion for summary judgment and was granted in July 2016. The trial on this matter has been set for March 2017. The company intends to vigorously defend the allegations asserted by Gore. The company cannot give any assurances that an adverse resolution of this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Part I, Item 1A. in Bard’s 2015 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information with respect to the shares of the company’s common stock repurchased during the quarter ended September 30, 2016:


	Issuer Purchases of Equity Securities
Period	Total Number of Shares Purchased⁽¹⁾		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs⁽²⁾		Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs⁽²⁾
July 1 – July 31, 2016		1,563	$	234.96		—	$	706,488,377
August 1 – August 31, 2016		191,914		220.46		190,000		664,610,207
September 1 – September 30, 2016		4,225		217.81		—		664,610,207

Total		197,702	$	220.52		190,000	$	664,610,207

(1)

Includes 7,702 shares that the company repurchased during the three month period ended September 30, 2016 that were not part of the publicly announced share repurchase authorization. These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares/units from equity-based awards.

(2)

On June 10, 2015, the company announced that its Board of Directors had authorized the repurchase of up to $500 million of common stock of the company. On June 8, 2016, the company announced that its Board of Directors had authorized the repurchase of up to an additional $500 million of common stock.

Item 5. Other Information

The company’s policy governing transactions in its securities by the company’s directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. From time-to-time, the company’s executive officers have established trading plans relating to the company’s common stock under Rule 10b5-1, and the company anticipates additional trading plans may be established in the future. The company currently discloses details regarding individual trading plans on its website.

Item 6. Exhibits


Number		Description

12.1		Computation of Ratio of Earnings to Fixed Charges*

31.1		Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer*

31.2		Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer*

32.1		Section 1350 Certification of Chief Executive Officer (furnished herewith)

32.2		Section 1350 Certification of Chief Financial Officer (furnished herewith)

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema Document*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB		XBRL Taxonomy Extension Label Linkbase Document*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	C. R. BARD, INC.
		(Registrant)

Date: October 26, 2016

		/s/ CHRISTOPHER S. HOLLAND
		Christopher S. Holland Senior Vice President and Chief Financial Officer

		/s/ FRANK LUPISELLA JR.
		Frank Lupisella Jr. Vice President and Controller

INDEX TO EXHIBITS


Number		Description

12.1		Computation of Ratio of Earnings to Fixed Charges

31.1		Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer

31.2		Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer

32.1		Section 1350 Certification of Chief Executive Officer (furnished herewith)

32.2		Section 1350 Certification of Chief Financial Officer (furnished herewith)

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-12.1 2 d253269dex121.htm EX-12.1 EX-12.1

EXHIBIT 12.1

C. R. BARD, INC. AND SUBSIDIARIES

Exhibit 12.1 - Computation of Ratio of Earnings to Fixed Charges


	Nine Months Ended September 30, 2016		Years Ended December 31,
	Nine Months Ended September 30, 2016		2015		2014		2013			2012			2011
(dollars in millions)
Earnings from operations before taxes	$	462.8	$	349.4	$	445.8	$	1,213.4		$	732.4		$	510.8
Add (Deduct):
Fixed charges		45.5		52.8		52.9		52.4			46.1			42.7
Undistributed earnings of equity investments		—		0.4		0.3		(1.0	)		(9.6	)		(3.8	)

Earnings available for fixed charges	$	508.3	$	402.6	$	499.0	$	1,264.8		$	768.9		$	549.7

Fixed charges:
Interest, including amounts capitalized⁽¹⁾	$	39.6	$	44.9	$	44.8	$	45.0		$	39.6		$	36.4
Proportion of rent expense deemed to represent interest factor		5.9		7.9		8.1		7.4			6.5			6.3

Fixed charges	$	45.5	$	52.8	$	52.9	$	52.4		$	46.1		$	42.7

Ratio of earnings to fixed charges		11.17		7.63		9.43		24.14			16.68			12.87

⁽¹⁾	Interest related to unrecognized tax benefits is included as income tax expense and not included in fixed charges.

EX-31.1 3 d253269dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

I, Timothy M. Ring, certify that:

I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2016

/s/ Timothy M. Ring

Timothy M. Ring

Chief Executive Officer

EX-31.2 4 d253269dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

I, Christopher S. Holland, certify that:

I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2016

/s/ Christopher S. Holland

Christopher S. Holland

Senior Vice President and Chief Financial Officer

EX-32.1 5 d253269dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy M. Ring, Chairman and Chief Executive Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

/s/ Timothy M. Ring

Name: Timothy M. Ring

Date: October 26, 2016

EX-32.2 6 d253269dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher S. Holland, Senior Vice President and Chief Financial Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

/s/ Christopher S. Holland

Name: Christopher S. Holland

Date: October 26, 2016

EX-101.INS 7 bcr-20160930.xml XBRL INSTANCE DOCUMENT 300 200000

1.00

16600000

22500000

-2900000

36100000

0.175

0.02875

250000000

0.03000

500000000

100000

4300000

0.03000

250000000

1001700000

-10600000

-80800000

-64500000

-155900000

600000000

73526324

0.25

73526324

5000000

18200000

-400500000

960600000

5310700000

170300000

-210600000

95700000

3300000

1722100000

1066400000

1641200000

-2600000

18400000

2314800000

390000000

21800000

111700000

10500000

20900000

875100000

588200000

2302400000

3000000

32900000

92900000

476900000

996400000

116100000

20800000

109900000

487700000

455800000

866900000

153500000

5310700000

712100000

1268800000

161500000

293300000

191700000

338000000

135400000

1000000000

19700000

1748700000

-12300000

200000

79100000

4670191

26102

404300000

11400000

300000

2500000

60300000

1300000

200000

13900000

1800000

1005

-24600000

-100000000

-86000000

-210600000

45900000

4 4200000 321400000 200

960100000

900000

-86600000

-3100000

-88800000

600000000

73697371

0.25

73697371

5000000

-503500000

936700000

4939200000

187900000

-208000000

70700000

2800000

1455300000

1174300000

1144100000

18400000

2148400000

335400000

22300000

141300000

250200000

7500000

23000000

1261800000

730000000

2093200000

23800000

79600000

472400000

950500000

123900000

21800000

413700000

445100000

807800000

80400000

4939200000

744300000

1140600000

137600000

252300000

192100000

274800000

132800000

132100000

11200000

1449800000

-7800000

-3300000

3800000

66000000

516500000

6200000

8000000

50300000

2900000

200000

3800000

14200000

6900000

-8700000

-105100000

-94200000

-208000000

191600000

53000000

26000000

1.00

31600000

11900000

21000000

4400000

495600000

2026 2026 2

5 3 5 1

10110

655 P12M 980 9860 1

105

P12M

1055

1 P12M 40 1 1

P12Y

P8Y

181100000

121800000

676500000 71600000 524800000

23300000

1300000

-0.01

681300000

74200000

-0.01

2545200000

79300000

386300000

74500000

-11500000

-67300000

14200000

5700000

-69700000

-900000

37400000

3900000

38500000

-5100000

-68000000

4000000

700000

51600000

-61400000

135900000

-700000

-416300000

-3900000

-67100000

-900000

191400000

61100000

-32800000

-26800000

192300000

33700000

590000000

-168700000

-900000

61100000

143000000

32000000

-78000000

732800000

2353800000

-444200000

-5800000

-2400000

-200000

189800000

41600000

981200000

57200000

-133800000

16300000 14600000 50600000 6900000

731000000

627100000

419500000

699100000

68500000

-5900000

-8300000

2400000

-11500000

8000000

-2400000

5600000

-3100000

5800000

-8900000

-5800000

-61400000

322600000

125800000

1772600000

324200000

23500000

-8900000

15100000

22600000

22100000

-5400000

-1000000

-10700000

8000000

9000000

-8100000

8000000

<div> 7. Contingencies In the ordinary course of business, the company is subject to various legal proceedings, investigations and claims, including, for example, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant product liability and patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. If the estimate of a probable loss is a range and no amount within the range is more likely, the company accrues the minimum amount of the range. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company is found to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. Many of the company’s legal proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.   Product Liability Matters Hernia Product Claims As of September 30, 2016, approximately 30 federal and 80 state lawsuits involving individual claims by approximately 105 plaintiffs, as well as one putative class action in the United States, are currently pending against the company with respect to its Composix® Kugel® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). The company voluntarily recalled certain sizes and lots of the Composix® Kugel® products beginning in December 2005. In June 2007, the Composix® Kugel® lawsuits and, subsequently, other hernia repair product lawsuits, pending in federal courts nationwide were transferred into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL stopped accepting new cases in the second quarter of 2014. As of September 30, 2016, all but one of the putative class actions pending against the company were dismissed. The remaining putative class action pending against the company has not been certified and seeks: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2014, a settlement was reached with respect to the three putative Canadian class actions within amounts previously recorded by the company. Approximately 60 of the state lawsuits, involving individual claims by approximately 60 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products. The company has resolved the majority of its historical Hernia Product Claims, including through agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases. Each agreement involving the settlement of a firm’s inventory of claims was subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The company expects additional trials of Hernia Product Claims to take place over the next 12 months. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuit, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2016, product liability lawsuits involving individual claims by approximately 10,110 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, which includes products manufactured by both the company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the company. Medtronic has an obligation to defend and indemnify the company with respect to any product defect liability. As described below, in July 2015 the company reached an agreement with Medtronic regarding certain aspects of Medtronic’s indemnification obligation. In addition, five putative class actions in the United States and five putative class actions in Canada have been filed against the company, and a limited number of other claims have been filed or asserted in various non-U.S. jurisdictions. The foregoing lawsuits, unfiled or unknown claims, putative class actions and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims”. The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) compensatory damages; (iii) punitive damages; (iv) a judicial finding of defect and causation; and/or (v) attorneys’ fees. In April 2015, the Ontario Superior Court of Justice dismissed the plaintiffs’ motion for class certification in one Canadian putative class action. In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company. The company expects administration of those settlements to take place over the next several quarters. In October 2010, the Women’s Health Product Claims involving solely Avaulta® products pending in federal courts nationwide were transferred into an MDL in the United States District Court for the Southern District of West Virginia (the “WV District Court”), the scope of which was later expanded to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. The first trial in a state court was completed in California in July 2012 and resulted in a judgment against the company of approximately $3.6 million. On appeal the decision was affirmed by the appellate court in November 2014. The company filed a petition for review to the California Supreme Court on December 24, 2014, which was denied on February 18, 2015. The judgment in this matter, including interest and costs, was paid on March 20, 2015 within the amounts previously recorded by the company. The first trial in the MDL commenced in July 2013 and resulted in a judgment against the company of approximately $2 million, which was upheld by the Fourth Circuit on January 14, 2016. The company does not believe that any verdicts entered to date are representative of potential outcomes of all Women’s Health Product Claims. On January 16, 2014 and July 31, 2014, the WV District Court ordered that the company prepare 200 and then an additional 300 individual cases, respectively, for trial (the “WHP Pre-Trial Orders”) (the timing for which is currently unknown). The WHP Pre-Trial Orders resulted in significant additional litigation-related defense costs beginning in the second quarter of 2014 and continuing through the second quarter of 2015. In February 2015, the WV District Court appointed a Special Master to assist with settlement resolution. In June 2015, the WV District Court issued an order staying the requirement to prepare a significant portion of the cases covered by the WHP Pre-Trial Orders, which stay could be modified at the court’s discretion. The WHP Pre-Trial Orders may result in material additional cost in future periods in defending Women’s Health Product Claims. The WV District Court may also order that the company prepare additional cases for trial, which could result in material additional costs in future periods. As of September 30, 2016, the company reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 9,860 Women’s Health Product Claims, including approximately: 560 during 2014, 6,285 during 2015 and 3,015 during 2016. The company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which have not been included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Notwithstanding these settlement efforts, the company anticipates additional trials over the next 12 months. In addition, one or more possible consolidated trials may occur in the future. In July 2015, as part of the agreement noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the company under supply agreements with Medtronic and the company has paid Medtronic $121 million towards these potential settlements. The company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreement does not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. As part of the agreement, Medtronic and the company agreed to dismiss without prejudice their previously filed litigation with respect to Medtronic’s obligation to defend and indemnify the company. The approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 655 generic complaints involving women’s health products where the company cannot, based on the allegations in the complaints, determine whether any of those cases involve the company’s women’s health products. In addition, the approximate number of lawsuits set forth in the first paragraph of this section does not include approximately 980 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. During the course of engaging in settlement discussions with plaintiffs’ law firms, the company has learned, and may in future periods learn, additional information regarding these and other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. While the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims and intends to vigorously defend the Women’s Health Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. Filter Product Claims As of September 30, 2016, product liability lawsuits involving individual claims by approximately 1,055 plaintiffs are currently pending against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products (all lawsuits, collectively, the “Filter Product Claims”). In August 2015, the Judicial Panel for Multi-District Litigation (“JPML”) ordered the creation of a Multi-District Litigation for all federal Filter Product Claims (the “IVC Filter MDL”) in the District of Arizona. There are approximately 1,005 Filter Product Claims that have been, or shortly will be, transferred to the IVC Filter MDL. The remaining approximately 50 Filter Product Claims are pending in various state courts. In March 2016, a Canadian class action was filed against the company in Quebec. In April 2016 and May 2016, Canadian class actions were filed in Ontario and British Columbia, respectively. The approximate number of lawsuits set forth above does not include approximately 40 claims that have been threatened against the company but for which complaints have not yet been filed. In addition, the company has limited information regarding the nature and quantity of these and other unfiled or unknown claims. The company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the company’s estimate of the number of claims or lawsuits against the company. The company expects that additional trials of Filter Product Claims may take place over the next 12 months. While the company intends to vigorously defend Filter Product Claims that do not settle, including through litigation, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. General In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. The company believes that some settlements and judgments, as well as some legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the company from other parties. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. In addition, other parties may dispute their indemnification obligations to the company with respect to certain claims. When either of these occur, the company intends to vigorously contest disputes with respect to its insurance coverage or indemnification and to enforce its rights, and accordingly, will record expected recoveries with respect to amounts due under these policies or arrangements, when recovery is probable. Amounts recovered under the company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. The company’s insurance coverage with respect to the Hernia Product Claims has been exhausted. The company continues to evaluate its available insurance coverage as it relates to Women’s Health Product Claims and Filter Product Claims. Other Legal Matters Since early 2013, the company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. In November 2015, the Department of Defense Inspector General issued an investigative subpoena to the company. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. The company is cooperating with these requests. Since it is not feasible to predict the outcome of these proceedings, the company cannot give any assurances that the resolution of these proceedings will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. In June 2011, Gore filed suit in the U.S. District Court in Delaware alleging the company had infringed on several of Gore’s patents. Fact and expert discovery have been completed and in the fourth quarter of 2014, the parties both filed a number of motions, including motions for summary judgment. Oral arguments on the motions occurred on January 30, 2015. In December 2015, the Delaware District Court granted the company’s summary judgment motion of no willful infringement. However, that decision was vacated in June 2016 due to a United States Supreme Court ruling that changed the test for willful infringement historically applied by the lower courts. In July 2016, the company’s summary judgment motion of laches (undue delay) was denied, at least in part because the Supreme Court will be hearing a case on this issue during the Fall 2016 term. In the third quarter of 2015, the company filed a motion to dismiss a significant portion of Gore’s damages claim on the grounds that Gore lacks proper standing. This motion was converted to a motion for summary judgment and was granted in July 2016. The trial on this matter has been set for March 2017. The company intends to vigorously defend the allegations asserted by Gore. The company cannot give any assurances that an adverse resolution of this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.   The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations. Litigation Reserves The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. In the second quarter of 2014, the company recorded a charge, net of estimated recoveries to other (income) expense, net, of approximately $259 million ($238 million after tax) related to certain of the product liability matters discussed above under the heading “Product Liability Matters”. The company recorded this charge based on additional information obtained during the quarter, including but not limited to: the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the company; and the procedural posture and stage of litigation. Specifically, the company considered its discussions with plaintiffs’ counsel, the increase in the rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims), and the value, number of cases and nature of the inventory of cases with respect to the recent settlements of claims by the company and other manufacturers. In the second quarter of 2015, the company recorded an additional charge related to these matters, net of estimated recoveries to other (income) expense, net, of approximately $337 million ($325 million after tax). The company recorded this charge based on additional information obtained during the quarter, including with respect to the factors noted above. Specifically the company considered the agreement and the agreement in principle by the company to settle approximately 2,880 Women’s Health Product Claims, the involvement of the Special Master in settlement resolution, additional settlements by other manufacturers subject to product liability claims with respect to similar products, and the continued rate of claims being filed (which led the company to increase its estimate of future Women’s Health Product Claims). In the third quarter of 2015, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $241 million ($228 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered the agreements and the agreement in principle by the company to settle approximately 3,030 Women’s Health Product Claims, discussions with plaintiffs’ counsel, additional information learned regarding the nature and quantity of unfiled and unknown claims (which led the company to increase its estimate of future Women’s Health Product Claims), a reconciliation of claims in connection with settlements, additional settlements by other manufacturers subject to product liability claims with respect to similar products, the rate of claims being filed, and the creation of the IVC Filter MDL. In the first quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $49 million ($31 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter. Specifically, the company considered, among other factors, additional information learned regarding the nature and quantity of unfiled and filed claims, the increase in advertising by plaintiffs’ counsel with respect to IVC filters and an increase in the rate of claims being filed in Filter Product Claims (which led the company to increase its estimate of future Filter Product Claims). In the third quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $111 million ($77 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter, including with respect to the factors noted above. Specifically, the company considered, among other factors, additional information learned regarding Product Liability Matters, including regarding the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain Product Liability Matters (which led the company to increase its estimate of future claims for certain Product Liability Matters, including Filter Product Claims). These charges recognized the estimated costs for the product liability matters discussed above, including (with respect to such matters) filed and an estimate of unfiled and unknown claims, and costs to administer the settlements related to such matters. These charges exclude any costs associated with the putative class action lawsuits in the United States. The company cannot give any assurances that the actual costs incurred with respect to these product liability matters will not exceed the related amounts accrued. With respect to product liability claims that are not resolved through settlement, the company intends to vigorously defend against such claims, including through litigation. The company cannot give any assurances that the resolution of any of its product liability matters, including filed, unfiled and unknown claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. Accruals for product liability and other legal matters amounted to $1,066.4 million, of which $404.3 million was recorded to accrued expenses, and $1,174.3 million, of which $516.5 million was recorded to accrued expenses, at September 30, 2016 and December 31, 2015, respectively. The company has made total payments of $676.5 million to qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters since 2011, of which $289.3 million were made to QSFs during the nine months ended September 30, 2016. Payments to QSFs are recorded as a component of restricted cash. Total payments of $524.8 million from these QSFs have been made to qualified claimants, of which $216.1 million were made during the nine months ended September 30, 2016. In addition, other payments of $71.6 million have been made to qualified claimants, of which $9.1 million were made during the nine months ended September 30, 2016. The company recorded expected recoveries related to product liability matters amounting to $135.4 million, all of which was recorded to other assets, and $132.8 million, of which $132.1 million was recorded to other assets, at September 30, 2016 and December 31, 2015, respectively. The terms of the company’s agreement with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2016 and December 31, 2015 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreement. As described above, the agreement does not resolve the dispute between the company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits relating to product liability matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. In addition, with respect to the investigative subpoenas issued by various state and federal government agencies and other legal matters, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual issues to be resolved. With respect to Gore’s suit against the company alleging infringement of certain of Gore’s patents, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the stage of the proceedings; (ii) the company has not received and reviewed complete information in discovery; and/or (iii) there are significant factual and legal issues to be resolved. </div>

<div> 8. Share-Based Compensation Plans The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (the “LTIP”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. The total number of remaining shares at September 30, 2016 that may be issued under the LTIP was 4,670,191 and under the Directors’ Plan was 26,102. Awards under the LTIP may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company also has two employee stock purchase programs. For the quarters ended September 30, 2016 and 2015, amounts charged against income for share-based payment arrangements were $19.0 million and $17.0 million, respectively. For the nine months ended September 30, 2016 and 2015, amounts charged against income for share-based payment arrangements were $68.3 million and $61.1 million, respectively. In the first quarter of each of 2016 and 2015, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period based on pre-established targets over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may exceed an officer’s target payout; however, compensation cost initially recognized assumes that the target payout level will be achieved and may be adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair values of these units are based on the market price of the company’s stock on the date of the grant and use a Monte Carlo simulation model for the TSR component. The fair values of the TSR components of the 2016 and 2015 grants were estimated based on the following assumptions: risk-free interest rate of 0.83% and 0.86%, respectively; dividend yield of 0.52% and 0.51%, respectively; and expected life of 2.89 and 2.78 years, respectively. Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) are approximately 0.1 million shares for the 2016 grant. Purchases under the MSPP were approximately 0.2 million shares for the 2015 grant. The fair value of the 2016 annual MSPP purchases was $83.23 per share and was estimated in July 2016. The fair value of the 2015 annual MSPP purchases was $60.47 per share. These fair value calculations used the Black-Scholes model based on the following assumptions: risk free interest rate of 0.39% and 0.16%, respectively; expected volatility of 18% and 17%, respectively; dividend yield of 0.5% and 0.6%, respectively; and expected life of 0.6 years for both valuations. As of September 30, 2016, there were $109.9 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2016. </div>

Q3 2016 10-Q

4.92

0000009892

<div> 6. Inventories Inventories consisted of:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">293.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">252.3</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">487.7</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">413.7</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

344200000

<div> The changes in accumulated other comprehensive income (loss) by component are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Instruments Designated as Cash Flow Hedges</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign Currency Translation Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Benefit Plans</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(88.8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69.7</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Tax (provision) benefit (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) before reclassifications, net of taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(67.3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.0</td> <td valign="bottom" nowrap="nowrap">)(b) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.9</td> <td valign="bottom" nowrap="nowrap">(c) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tax provision (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Reclassifications, net of tax </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(11.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(67.1</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(64.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(80.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(155.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(94.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(105.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(208.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tax (provision) benefit (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) before reclassifications, net of taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14.4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">(b) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.8</td> <td valign="bottom" nowrap="nowrap">(c) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Tax provision (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassifications, net of tax </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(100.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(210.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(a)</td> <td valign="top" align="left">Income taxes are not provided for foreign currency translation adjustment.</td> </tr> </table> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(b)</td> <td valign="top" align="left">See Note 5 of the notes to condensed consolidated financial statements.</td> </tr> </table> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(c)</td> <td valign="top" align="left">These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.</td> </tr> </table> </div>

<div> The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contracts </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7.8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

<div> Net sales based on the location of external customers by geographic region are:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">646.0</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">606.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,904.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,772.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">108.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107.4</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">322.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Japan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">125.8</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">363.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">941.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">865.7</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,746.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,545.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 10. Shareholders’ Investment The company repurchased approximately 1.2 million shares of common stock for $231.8 million in the nine months ended September 30, 2016 under its previously announced share repurchase authorizations. Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Instruments Designated as Cash Flow Hedges</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign Currency Translation Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Benefit Plans</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(88.8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69.7</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Tax (provision) benefit (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) before reclassifications, net of taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(67.3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.0</td> <td valign="bottom" nowrap="nowrap">)(b) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.9</td> <td valign="bottom" nowrap="nowrap">(c) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tax provision (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.7</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Reclassifications, net of tax </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other comprehensive income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(11.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(61.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(67.1</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(64.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(80.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(155.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(94.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(105.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(208.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tax (provision) benefit (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) before reclassifications, net of taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14.4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassifications </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.6</td> <td valign="bottom" nowrap="nowrap">(b) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.8</td> <td valign="bottom" nowrap="nowrap">(c) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Tax provision (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassifications, net of tax </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other comprehensive income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(100.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(210.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(a)</td> <td valign="top" align="left">Income taxes are not provided for foreign currency translation adjustment.</td> </tr> </table> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(b)</td> <td valign="top" align="left">See Note 5 of the notes to condensed consolidated financial statements.</td> </tr> </table> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">(c)</td> <td valign="top" align="left">These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.</td> </tr> </table> </div>

BCR

75200000

74000000

false

<div> 4. Income Taxes The company’s effective tax rate for the quarter and nine months ended September 30, 2016 was 14.1% and 19.7%, respectively. The effective tax rate for the quarter and nine months ended September 30, 2016 reflected the discrete tax effects of litigation charges related to product liability claims, which were substantially incurred in a high tax jurisdiction and a benefit of $2.6 million related to the completion of certain U.S. Internal Revenue Service examinations. See Note 7 of the notes to condensed consolidated financial statements. The effective tax rate for the quarter and nine months ended September 30, 2015 reflected the discrete tax effects of litigation charges, primarily related to product liability claims, which were substantially incurred in a low tax jurisdiction. The effective tax rate for the nine months ended September 30, 2015 also reflected the discrete tax effects of the gain related to the proceeds received from W. L. Gore & Associates, Inc. (“Gore”), which was incurred in a high tax jurisdiction. See Note 7 of the notes to condensed consolidated financial statements. At September 30, 2016, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $21.8 million (of which $18.2 million would impact the effective tax rate, if recognized) plus $3.3 million of accrued interest. At December 31, 2015, the liability for unrecognized tax benefits was $22.3 million plus $2.8 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $3.0 million within the next 12 months. </div>

<div> 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2015 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2015 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarters ended August 31, 2016 and August 31, 2015 and as of November 30, 2015. No events occurred related to these foreign subsidiaries during the months of September 2016, September 2015 or December 2015 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year. Recently Adopted Accounting Pronouncement In April 2015, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires debt issuance costs to be presented as a direct deduction from the carrying amount of the related debt rather than as an asset. In 2016, the company retrospectively adopted this update, as required, and the amounts reclassified from other assets to long-term debt on the consolidated balance sheets were not material. New Accounting Pronouncements Not Yet Adopted In March 2016, the FASB issued an accounting standard update that includes multiple provisions intended to simplify various aspects of the accounting for share-based payments, including the income tax items and the classification of these items on the statement of cash flows. This update will be effective as of the beginning of Bard’s 2017 fiscal year. The company is assessing this update and has not yet determined the impact to the consolidated financial statements. In February 2016, the FASB issued a new accounting standard to use in the accounting for leases. The new standard will require, among other items, lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This standard will be effective as of the beginning of Bard’s 2019 fiscal year. The company is assessing the new standard and has not yet determined the impact to the consolidated financial statements. In November 2015, the FASB issued an accounting standard update that simplifies the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the balance sheet. This update will be effective as of the beginning of Bard’s 2017 fiscal year. Other than the reclassification to non-current of the short-term deferred tax assets and liabilities recognized in the consolidated balance sheets, this update is not expected to have a material impact on the company’s consolidated financial statements. In May 2014, the FASB issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The company continues to assess the new standard, as well as updates to the standard that have been proposed by the FASB, and has not yet determined the impact to the consolidated financial statements. The company will adopt the new standard beginning with Bard’s 2018 fiscal year. </div>

<div> The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Balance Sheet Location</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Fair Value of Derivatives</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Derivatives Designated as Hedging Instruments </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Accrued expenses</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Accrued expenses</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other long-term liabilities</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Inventories consisted of:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">293.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">252.3</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">487.7</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">413.7</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1200000

<div> 2. Acquisitions On January 21, 2016, the company acquired all of the outstanding shares of Liberator Medical Holdings, Inc. (“Liberator”), a publicly-held direct-to-consumer distributor of urological catheters, ostomy supplies, mastectomy fashions and diabetic medical supplies for a purchase price of $181.1 million. This acquisition enhanced the company’s position in the home healthcare market in the United States. The acquisition was accounted for as a business combination, and the results of operations have been included in the company’s results since the acquisition date. The fair value of the assets acquired and the liabilities assumed results in the recognition of: customer relationships of $53.0 million; other intangibles of $26.0 million, primarily consisting of a trade name and non-compete agreements; deferred tax liabilities of $31.6 million, primarily associated with intangible assets; and other net assets of $11.9 million. The excess of the purchase price over fair value of the acquired net assets was recorded as goodwill of $121.8 million. The goodwill recognized includes the value of expected market expansion in the home healthcare market through Liberator’s direct-to-consumer capabilities that provide additional opportunity for market penetration. Additionally, synergies are expected to result from the alignment of sales call points within the company’s sales organization. The goodwill is not deductible for tax purposes. Customer relationships and other intangible assets are being amortized over their weighted average estimated useful lives of approximately 12 years and 8 years, respectively. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available. On December 3, 2015, the company, through a wholly-owned foreign subsidiary, acquired all of the outstanding shares of Embo Medical Limited (“Embo”), a privately-held company headquartered in Galway, Ireland, specializing in the development of peripheral embolization devices. The total purchase consideration included an up-front cash payment of $21.0 million and the fair value of future additional milestone payments of up to $22.5 million that are contingent upon specific regulatory and revenue-related milestones being achieved, which had a fair value of $16.6 million as of the acquisition date. The acquisition was recognized in the first quarter of 2016 for this foreign subsidiary. The fair value of the assets acquired and the liabilities assumed resulted in the recognition of: an acquired in-process research and development asset (“IPR&D”) of $36.1 million related to the development of the CaterpillarTM vascular plug device; goodwill of $4.4 million; and other net liabilities of $2.9 million. The goodwill is not deductible for tax purposes. The fair value of the IPR&D asset was determined based upon the present value of expected future cash flows adjusted for the probability of technological and regulatory success, utilizing a risk-adjusted discount rate of 17.5%. The fair value of the future contingent consideration was determined utilizing a probability weighted cash flow estimate adjusted for the expected timing of the payment. The company has not yet finalized the purchase accounting, which may be adjusted as further information about conditions existing at the acquisition date become available. </div>

--12-31 2016-09-30

5.00

Large Accelerated Filer

<div> 5. Financial Instruments For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2015 Annual Report on Form 10-K. Foreign Exchange Derivative Instruments The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $321.4 million and $191.6 million at September 30, 2016 and December 31, 2015, respectively. Interest Rate Derivative Instruments In January 2016, the company’s outstanding interest rate swap contract was terminated concurrent with the maturity of the underlying 2.875% fixed-rate notes. The notional value of the company’s interest rate swap contract was $250 million and effectively converted these fixed-rate notes to a floating-rate instrument. In May 2016, the company’s forward starting interest rate swap contract was settled concurrent with the issuance of 3.000% fixed-rate notes due 2026. The fair value of the forward starting interest rate swap contract at settlement recorded in accumulated other comprehensive loss was a loss of $23.3 million. This loss will be recognized as interest expense over the term of these notes. The notional value of the company’s forward swap contract was $250 million. The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Balance Sheet Location</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Fair Value of Derivatives</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Derivatives Designated as Hedging Instruments </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other current assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other assets</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Accrued expenses</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="bottom"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Accrued expenses</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">Other long-term liabilities</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="43%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Recognized in Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center">Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom" rowspan="3"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center"> Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Interest expense</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> <td height="16" colspan="4"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Recognized in Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center">Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom" rowspan="3"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center"> Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Interest expense</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(33.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Financial Instruments Measured at Fair Value on a Recurring Basis Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that is determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs. The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.3</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contracts </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7.8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy. The fair value of the liability for contingent consideration related to acquisitions was $19.7 million and $11.2 million at September 30, 2016 and December 31, 2015, respectively. The increase in the fair value of the liability for contingent consideration was primarily related to the addition of contingent consideration due to the acquisition of Embo and was partly offset by a reduction in the probability of the achievement of other unrelated revenue-based and manufacturing-related milestones. See Note 2 of the notes to condensed consolidated financial statements. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy. Financial Instruments Not Measured at Fair Value The company maintains a $1 billion five-year committed syndicated bank credit facility that expires in November 2020. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2016 the company was in compliance with this covenant. There were no commercial paper borrowings outstanding at September 30, 2016 or December 31, 2015. On May 9, 2016, the company issued $500 million aggregate principal amount of 3.000% senior unsecured notes due 2026. Interest on the notes is payable semi-annually. Net proceeds from this offering were approximately $495.6 million, after deducting debt offering costs, consisting of underwriting commissions and offering expenses of $4.3 million and a debt issuance discount of $0.1 million, which were both recorded to long-term debt. The debt offering costs and debt issuance discount will be amortized over the term of the notes. Net proceeds from the issuance of the notes were used for general corporate purposes, including repayment of outstanding commercial paper. The estimated fair value of long-term debt (including current maturities and the effect of the related interest rate swap contract for the prior year period) was approximately $1,748.7 million and $1,449.8 million at September 30, 2016 and December 31, 2015, respectively. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation and is categorized as Level 2 under the fair value hierarchy. The fair value of the non-contingent future payments related to the Medicon, Inc. acquisition of $79.1 million and $66.0 million at September 30, 2016 and December 31, 2015, respectively, approximated the carrying value. At September 30, 2016 and December 31, 2015, future payments of $60.3 million and $50.3 million, respectively, were recorded to other long-term liabilities. These payments will be paid in Japanese Yen and are subject to exchange rate fluctuations. The fair value was estimated by discounting the future payments based upon the timing of such payments and is categorized as Level 2 under the fair value hierarchy. Concentration Risk Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company monitors economic conditions and evaluates accounts receivable in certain countries for potential collection risks. Economic conditions and other factors in certain countries, particularly in Spain, Italy, Greece and Portugal, have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. At September 30, 2016, the company’s accounts receivable, net of allowances, from the national healthcare systems and private sector customers in these four countries was $45.9 million, of which $4.2 million was greater than 365 days past due. </div>

<div> 9. Pension Plans The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service. The components of net periodic pension cost are as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Service cost, net of employee contributions </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.0</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Interest cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected return on plan assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.0</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7.9</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24.2</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23.5</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.9</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net periodic pension cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> In 2016, the company changed its method used to estimate the service and interest cost components of net periodic benefit cost for defined benefit plans from a single weighted-average discount rate to a full yield curve approach. The reduction in service and interest cost for the quarter and nine months ended September 30, 2016 associated with this change in estimate was approximately $1.2 million and $3.8 million, respectively. </div>

<div> The components of net periodic pension cost are as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Service cost, net of employee contributions </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.0</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Interest cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected return on plan assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8.0</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7.9</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24.2</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23.5</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.9</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net periodic pension cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.5</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.8</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.6</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 3. Earnings per Common Share Earnings per share (“EPS”) is computed under the two-class method using the following common share information:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars and shares in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> EPS Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">371.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: Income allocated to participating securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) available to common shareholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> EPS Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Dilutive common share equivalents from share-based compensation plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average common and common equivalent shares outstanding, assuming dilution </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For both the quarter and nine months ended September 30, 2015, common share equivalents of approximately 1.3 million were not included in the computation of diluted weighted average shares outstanding. Common share equivalents primarily from share-based compensation plans were not included in these periods because their effect would have been anti-dilutive. </div>

0.197

BARD C R INC /NJ/

P2Y

<div> The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="43%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Recognized in Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center">Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom" rowspan="3"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center"> Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.6</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Interest expense</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(18.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> <td height="16" colspan="4"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Recognized in Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="3" colspan="2" align="center">Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom" rowspan="3"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forward currency contracts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center"> Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Option currency contracts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Cost of goods sold</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest rate swap contract </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">Interest expense</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(33.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Earnings per share (“EPS”) is computed under the two-class method using the following common share information:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars and shares in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> EPS Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">371.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: Income allocated to participating securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) available to common shareholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(86.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.9</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> EPS Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Dilutive common share equivalents from share-based compensation plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average common and common equivalent shares outstanding, assuming dilution </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Total net sales by product group category are:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vascular </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">258.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">250.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">752.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">731.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Urology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">242.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">212.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">698.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">627.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Oncology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">239.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">752.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Surgical Specialties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">419.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">941.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">865.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,746.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,545.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 11. Segment Information The company’s management considers its business to be a single segment entity – the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.   Net sales based on the location of external customers by geographic region are:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">646.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">606.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,904.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,772.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">108.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">322.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Japan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">60.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">125.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">363.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">324.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">941.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">865.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,746.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,545.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Total net sales by product group category are:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Quarter Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">(dollars in millions)</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vascular </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">258.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">250.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">752.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">731.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Urology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">242.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">212.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">698.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">627.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Oncology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">239.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">752.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">699.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Surgical Specialties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">419.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">941.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">865.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,746.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,545.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2746900000

64600000

231800000

202800000

-15900000

-14400000

73100000

17100000

-22900000

371800000

37100000

5100000

78700000

-10300000

369200000

250000000

600000

55300000

8200000

118000000

-2600000

-185400000

-2100000

-2600000

370000000

462800000

68300000

-42800000

900000

91000000

39600000

159200000

-341100000

-14400000

68300000

231800000

1200000

160700000

35300000

821700000

2284100000

41900000

-5100000

-8500000

-11800000

213800000

1800000

45900000

1023600000

-19500000

-310400000

495600000

289300000 9100000 216100000 P12M 23300000 2 3800000 49800000 1700000

-3800000

P5Y

2020-11

Semi-annually

752900000

698800000

470100000

752700000

72400000

-22600000

-31100000

100000

-15900000

-6600000

-8500000

-6700000

-2700000

5100000

-7800000

-5100000

8200000

328600000

In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company.

150500000

1904500000

363300000

24200000

-7800000

14200000

19800000

22000000

-15300000

-5900000

-15300000

-900000

-3300000

200000

-33900000

-6600000

3015 121000000 3 1 1

3600000

2000000

P7M6D

0.006

0.0016

0.17

60.47

P7M6D

0.005

0.0039

0.18

83.23 100000 560 6285

P3Y

P2Y9M11D

0.0051

0.0086

238000000

259000000

325000000 2880

337000000

31000000

P3Y

P2Y10M21D

0.0052

0.0083

P3Y

49000000

1300000

-1.16

74100000

-1.16

865700000

-15400000

-86000000

-96200000

3200000

-258300000

-10200000

-86000000

-52400000

17000000

33600000

11200000

247100000

918100000

-2000000

65200000

336300000

228000000

250500000

212300000

139800000

239300000

23800000

107400000

41600000

606500000

110200000

7900000

-3100000

5200000

7500000

7100000

-3600000

-1600000

-12900000

-2400000

4500000

-18900000

2900000

3030

241000000

1.27

75300000

74100000

1200000

1.30

0.141

941900000

-400000

96400000

85200000

-12500000

-115800000

-11200000

96000000

112200000

19000000

15800000

14900000

272600000

829700000

-1700000

74200000

400000

352200000

77000000

-1200000

258100000

242100000

158800000

258400000

24500000

108600000

60100000

646000000

127200000

8000000

-2600000

4800000

6900000

7500000

-3500000

-1200000

-500000

-300000

-800000

-3800000

-2500000

111000000

0000009892 us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-01 2016-09-30 0000009892 us-gaap:CashFlowHedgingMember 2016-07-01 2016-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember 2016-07-01 2016-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2016-07-01 2016-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember 2016-07-01 2016-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember 2016-07-01 2016-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2016-07-01 2016-09-30 0000009892 bcr:OtherLocationMember 2016-07-01 2016-09-30 0000009892 country:US 2016-07-01 2016-09-30 0000009892 country:JP 2016-07-01 2016-09-30 0000009892 us-gaap:EuropeMember 2016-07-01 2016-09-30 0000009892 bcr:OtherProductGroupMember 2016-07-01 2016-09-30 0000009892 bcr:OncologyMember 2016-07-01 2016-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2016-07-01 2016-09-30 0000009892 bcr:UrologyMember 2016-07-01 2016-09-30 0000009892 bcr:VascularMember 2016-07-01 2016-09-30 0000009892 us-gaap:ChangeInAssumptionsForPensionPlansMember 2016-07-01 2016-09-30 0000009892 2016-07-01 2016-09-30 0000009892 us-gaap:OtherNonoperatingIncomeExpenseMember 2015-07-01 2015-09-30 0000009892 bcr:WomenSHealthProductClaimsMember 2015-07-01 2015-09-30 0000009892 us-gaap:CashFlowHedgingMember 2015-07-01 2015-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember 2015-07-01 2015-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2015-07-01 2015-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember 2015-07-01 2015-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember 2015-07-01 2015-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2015-07-01 2015-09-30 0000009892 bcr:OtherLocationMember 2015-07-01 2015-09-30 0000009892 country:US 2015-07-01 2015-09-30 0000009892 country:JP 2015-07-01 2015-09-30 0000009892 us-gaap:EuropeMember 2015-07-01 2015-09-30 0000009892 bcr:OtherProductGroupMember 2015-07-01 2015-09-30 0000009892 bcr:OncologyMember 2015-07-01 2015-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2015-07-01 2015-09-30 0000009892 bcr:UrologyMember 2015-07-01 2015-09-30 0000009892 bcr:VascularMember 2015-07-01 2015-09-30 0000009892 2015-07-01 2015-09-30 0000009892 us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-03-31 0000009892 bcr:PerformanceRestrictedStockUnitsMember 2016-01-01 2016-03-31 0000009892 2016-01-01 2016-03-31 0000009892 us-gaap:OtherNonoperatingIncomeExpenseMember 2015-04-01 2015-06-30 0000009892 bcr:WomenSHealthProductClaimsMember 2015-04-01 2015-06-30 0000009892 2015-04-01 2015-06-30 0000009892 us-gaap:OtherNonoperatingIncomeExpenseMember 2014-04-01 2014-06-30 0000009892 2014-04-01 2014-06-30 0000009892 bcr:PerformanceRestrictedStockUnitsMember 2015-01-01 2015-03-31 0000009892 bcr:WomenSHealthProductClaimsMember 2015-01-01 2015-12-31 0000009892 bcr:WomenSHealthProductClaimsMember 2014-01-01 2014-12-31 0000009892 bcr:ManagementStockPurchasePlanMember 2016-07-01 2016-07-31 0000009892 bcr:ManagementStockPurchasePlanMember 2015-07-01 2015-07-31 0000009892 bcr:MultiDistrictLitigationMemberbcr:WomenSHealthProductClaimsMember 2013-07-01 2013-07-31 0000009892 bcr:WomenSHealthProductClaimsMemberstpr:CA 2012-07-01 2012-07-31 0000009892 bcr:StateLawClaimsMemberbcr:SuperiorCourtOfStateOfRhodeIslandMemberbcr:HerniaProductClaimsMember 2007-06-01 2007-06-30 0000009892 bcr:OntarioSuperiorCourtOfJusticeMemberbcr:WomenSHealthProductClaimsMembercountry:CA 2015-04-01 2015-04-30 0000009892 bcr:HerniaProductClaimsMembercountry:CA 2014-04-01 2014-04-30 0000009892 bcr:WomenSHealthProductClaimsMemberbcr:MedtronicPlcMember 2015-07-01 2016-03-31 0000009892 bcr:WomenSHealthProductClaimsMember 2016-01-01 2016-09-30 0000009892 us-gaap:CashFlowHedgingMember 2016-01-01 2016-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember 2016-01-01 2016-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2016-01-01 2016-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember 2016-01-01 2016-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember 2016-01-01 2016-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2016-01-01 2016-09-30 0000009892 bcr:OtherLocationMember 2016-01-01 2016-09-30 0000009892 country:US 2016-01-01 2016-09-30 0000009892 country:JP 2016-01-01 2016-09-30 0000009892 bcr:WomenSHealthProductClaimsMembercountry:CA 2016-01-01 2016-09-30 0000009892 us-gaap:EuropeMember 2016-01-01 2016-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-09-30 0000009892 bcr:OtherProductGroupMember 2016-01-01 2016-09-30 0000009892 bcr:OncologyMember 2016-01-01 2016-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2016-01-01 2016-09-30 0000009892 bcr:UrologyMember 2016-01-01 2016-09-30 0000009892 bcr:VascularMember 2016-01-01 2016-09-30 0000009892 bcr:ThreePointZeroZeroZeroPercentSeniorUnsecuredNotesDueInTwentyTwentySixMember 2016-01-01 2016-09-30 0000009892 bcr:FiveYearCreditFacilityExpiringInNovemberTwoThousandTwentyMember 2016-01-01 2016-09-30 0000009892 us-gaap:ChangeInAssumptionsForPensionPlansMember 2016-01-01 2016-09-30 0000009892 bcr:PerformanceRestrictedStockUnitsMember 2016-01-01 2016-09-30 0000009892 2016-01-01 2016-09-30 0000009892 us-gaap:CashFlowHedgingMember 2015-01-01 2015-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0000009892 us-gaap:ForeignExchangeOptionMemberus-gaap:CashFlowHedgingMember 2015-01-01 2015-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember 2015-01-01 2015-09-30 0000009892 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember 2015-01-01 2015-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0000009892 us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember 2015-01-01 2015-09-30 0000009892 us-gaap:PensionPlansDefinedBenefitMember 2015-01-01 2015-09-30 0000009892 bcr:OtherLocationMember 2015-01-01 2015-09-30 0000009892 country:US 2015-01-01 2015-09-30 0000009892 country:JP 2015-01-01 2015-09-30 0000009892 us-gaap:EuropeMember 2015-01-01 2015-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-09-30 0000009892 bcr:OtherProductGroupMember 2015-01-01 2015-09-30 0000009892 bcr:OncologyMember 2015-01-01 2015-09-30 0000009892 bcr:SurgicalSpecialtiesMember 2015-01-01 2015-09-30 0000009892 bcr:UrologyMember 2015-01-01 2015-09-30 0000009892 bcr:VascularMember 2015-01-01 2015-09-30 0000009892 2015-01-01 2015-09-30 0000009892 bcr:ForwardStartingInterestRateSwapsMember 2016-05-10 2016-05-31 0000009892 2011-01-01 2016-09-30 0000009892 bcr:LiberatorMedicalHoldingsIncMember 2016-01-21 2016-01-21 0000009892 bcr:LiberatorMedicalHoldingsIncMemberus-gaap:OtherIntangibleAssetsMemberus-gaap:WeightedAverageMember 2016-01-21 2016-01-21 0000009892 bcr:LiberatorMedicalHoldingsIncMemberus-gaap:CustomerRelationshipsMemberus-gaap:WeightedAverageMember 2016-01-21 2016-01-21 0000009892 us-gaap:MinimumMember 2016-09-30 2016-09-30 0000009892 bcr:FilterProductClaimsMember 2016-09-30 2016-09-30 0000009892 bcr:HerniaProductClaimsMember 2016-09-30 2016-09-30 0000009892 bcr:WomenSHealthProductClaimsMemberus-gaap:MinimumMember 2016-09-30 2016-09-30 0000009892 bcr:WomenSHealthProductClaimsMember 2016-09-30 2016-09-30 0000009892 bcr:HerniaProductClaimsMembercountry:US 2016-09-30 2016-09-30 0000009892 bcr:WomenSHealthProductClaimsMembercountry:US 2016-09-30 2016-09-30 0000009892 bcr:FilterProductClaimsMembercountry:CA 2016-09-30 2016-09-30 0000009892 bcr:WomenSHealthProductClaimsMembercountry:CA 2016-09-30 2016-09-30 0000009892 bcr:StateLawClaimsMemberbcr:SuperiorCourtOfStateOfRhodeIslandMemberbcr:HerniaProductClaimsMember 2016-09-30 2016-09-30 0000009892 bcr:MedtronicPlcMemberbcr:WomenSHealthProductClaimsMember 2016-09-30 2016-09-30 0000009892 bcr:ThreePointZeroZeroZeroPercentSeniorUnsecuredNotesDueInTwentyTwentySixMemberbcr:ForwardStartingInterestRateSwapsMember 2016-05-09 2016-05-09 0000009892 bcr:ThreePointZeroZeroZeroPercentSeniorUnsecuredNotesDueInTwentyTwentySixMember 2016-05-09 2016-05-09 0000009892 bcr:EmboMedicalLimitedMember 2015-12-03 2015-12-03 0000009892 bcr:LiberatorMedicalHoldingsIncMember 2016-01-21 0000009892 bcr:LiberatorMedicalHoldingsIncMemberus-gaap:OtherIntangibleAssetsMember 2016-01-21 0000009892 bcr:LiberatorMedicalHoldingsIncMemberus-gaap:CustomerRelationshipsMember 2016-01-21 0000009892 us-gaap:ForeignExchangeContractMember 2015-12-31 0000009892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000009892 us-gaap:CommercialPaperMember 2015-12-31 0000009892 us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeOptionMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberbcr:MediconIncMember 2015-12-31 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000009892 us-gaap:AccruedLiabilitiesMember 2015-12-31 0000009892 bcr:MediconIncMemberus-gaap:FairValueInputsLevel2Member 2015-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember 2015-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember 2015-12-31 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember 2015-12-31 0000009892 us-gaap:FairValueInputsLevel2Member 2015-12-31 0000009892 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000009892 bcr:ReceivablesRelatedToProductLiabilityMattersMemberus-gaap:OtherAssetsMember 2015-12-31 0000009892 bcr:ReceivablesRelatedToProductLiabilityMattersMember 2015-12-31 0000009892 2015-12-31 0000009892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000009892 2014-12-31 0000009892 bcr:MultiDistrictLitigationMemberbcr:WomenSHealthProductClaimsMember 2014-01-16 0000009892 us-gaap:ForeignExchangeContractMember 2016-09-30 0000009892 bcr:NationalHealthcareSystemsAndPrivateSectorCustomersMemberbcr:SpainItalyGreeceAndPortugalMember 2016-09-30 0000009892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-09-30 0000009892 us-gaap:CommercialPaperMember 2016-09-30 0000009892 bcr:FederalLawClaimsMemberbcr:HerniaProductClaimsMember 2016-09-30 0000009892 bcr:MultiDistrictLitigationMemberbcr:FilterProductClaimsMember 2016-09-30 0000009892 bcr:StateLawClaimsMemberbcr:FilterProductClaimsMember 2016-09-30 0000009892 bcr:StateLawClaimsMemberbcr:SuperiorCourtOfStateOfRhodeIslandMemberbcr:HerniaProductClaimsMember 2016-09-30 0000009892 bcr:StateLawClaimsMemberbcr:HerniaProductClaimsMember 2016-09-30 0000009892 us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeOptionMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberbcr:MediconIncMember 2016-09-30 0000009892 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000009892 us-gaap:AccruedLiabilitiesMember 2016-09-30 0000009892 bcr:DirectorsPlanMember 2016-09-30 0000009892 bcr:TwoThousandTwelveLongTermIncentivePlanMember 2016-09-30 0000009892 bcr:MediconIncMemberus-gaap:FairValueInputsLevel2Member 2016-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember 2016-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember 2016-09-30 0000009892 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember 2016-09-30 0000009892 us-gaap:FairValueInputsLevel2Member 2016-09-30 0000009892 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000009892 bcr:FiveYearCreditFacilityExpiringInNovemberTwoThousandTwentyMember 2016-09-30 0000009892 bcr:ReceivablesRelatedToProductLiabilityMattersMemberus-gaap:OtherAssetsMember 2016-09-30 0000009892 bcr:ReceivablesRelatedToProductLiabilityMattersMember 2016-09-30 0000009892 2016-09-30 0000009892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0000009892 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-30 0000009892 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-09-30 0000009892 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-09-30 0000009892 2015-09-30 0000009892 bcr:ForwardStartingInterestRateSwapsMember 2016-05-31 0000009892 bcr:ThreePointZeroZeroZeroPercentSeniorUnsecuredNotesDueInTwentyTwentySixMemberbcr:ForwardStartingInterestRateSwapsMember 2016-05-09 0000009892 bcr:ThreePointZeroZeroZeroPercentSeniorUnsecuredNotesDueInTwentyTwentySixMember 2016-05-09 0000009892 us-gaap:InterestRateSwapMember 2016-01-31 0000009892 bcr:EmboMedicalLimitedMemberus-gaap:InProcessResearchAndDevelopmentMember 2015-12-03 0000009892 bcr:EmboMedicalLimitedMember 2015-12-03 0000009892 bcr:ManagementStockPurchasePlanMember 2015-07-31 0000009892 bcr:MultiDistrictLitigationMemberbcr:WomenSHealthProductClaimsMember 2014-07-31 bcr:LegalMatter shares pure iso4217:USD iso4217:USD shares bcr:Country bcr:Subsidiary bcr:Plaintiff bcr:Claim bcr:Trial bcr:Proceeding bcr:CompensationPlan Income taxes are not provided for foreign currency translation adjustment. See Note 5 of the notes to condensed consolidated financial statements. These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.

EX-101.SCH 8 bcr-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Acquisitions link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Earnings per Common Share link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Financial Instruments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Contingencies link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Share-Based Compensation Plans link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Pension Plans link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Shareholders' Investment link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Segment Information link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Earnings per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Pension Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Shareholders' Investment (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Acquisitions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Earnings Per Share Computation (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Earnings per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Share-Based Compensation Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Components of Net Periodic Pension Cost (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Pension Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Shareholders' Investment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) by Component (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Net Sales Based on Location of External Customer and Identifiable Assets by Geographic Region (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Total Net Sales by Product Group Category (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 bcr-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 bcr-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 bcr-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Receivable Type [Axis] Receivable Type [Axis] Accounts Payable, Current Accounts payable Accounts Receivable, Net Accounts receivable, net Accounts Receivable, Net, Current Accounts receivable, less allowances of $10,500 and $7,500, respectively Accounts receivable, net of allowances, greater than three hundred and sixty five days past due, country specific risk. Accounts Receivable Net Of Allowances Greater Than Three Hundred And Sixty Five Days Past Due Country Specific Risk Accounts receivable greater than 365 days past due Accrued Income Taxes, Current Income taxes payable Accrued Liabilities, Current Accrued expenses Accrued Liabilities [Member] Accrued Expenses Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Benefit Plans Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Derivative Instruments Designated as Cash Flow Hedges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Foreign Currency Translation Additional Paid in Capital Capital in excess of par value Period over which the company expects additional trials to take place. Additional Trials Period Period for additional product claims trials Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities, net of acquired businesses: Allocated Share-based Compensation Expense Share-based payment arrangements Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowances Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common share equivalents not included in computation of diluted weighted average shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Asset Impairment Charges Asset impairment Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets Award Type [Axis] Award Type [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Percentage of Voting Interests Acquired Percentage of outstanding stock acquired Business Acquisitions and Dispositions [Line Items] Business Acquisitions and Dispositions [Line Items] Business Acquisitions and Dispositions [Line Items] Business Acquisitions and Dispositions [Table] Business Acquisitions and Dispositions [Table] Business Acquisitions and Dispositions [Table] Business Combination, Consideration Transferred, Liabilities Incurred Purchases of businesses and related costs Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business acquisition, maximum contingent consideration Business Combination, Contingent Consideration, Liability Business combination, contingent consideration, liability Fair value of contingent consideration Business Combination Disclosure [Text Block] Acquisitions Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Purchase price allocation at fair value, recognition of deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Purchase price allocation at fair value, recognition of indefinite-lived intangible asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Purchase price allocation at fair value, recognition of finite-lived intangible asset Amount of other net assets (liabilities) assumed at the acquisition date not separately disclosed. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Asset (Liability) Business Combination, recognized identifiable assets acquired and liabilities assumed, other net assets and liabilities Business Combinations [Abstract] Business Combinations [Abstract] CALIFORNIA California state case CANADA Canada Cases That Could Be Settled At Any Time Cases That Could Be Settled At Any Time Cases that could be settled at any time Cash and Cash Equivalents, at Carrying Value Balance at September 30 Balance at January 1 Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Increase in cash and cash equivalents during the period Cash Flow Hedging [Member] Cash flow hedges Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash transactions: Cash Paid During Period For [Abstract] Cash Paid During Period For [Abstract] Cash paid for: Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Change in Assumptions for Pension Plans [Member] Change in Assumptions for Pension Plans The number of claims subject to an agreement or and agreement in principle. Claims Subject To Agreement And Agreement In Principle The number of claims subject to an agreement or an agreement in principle Class actions settled Class Actions Settled Class actions settled Commercial Paper [Member] Commercial Paper Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies Commitments and contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Contingencies Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, authorized Common Stock, Shares, Issued Common stock, issued Common Stock, Shares, Outstanding Common stock, outstanding Common Stock, Value, Issued Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 73,526,324 shares at September 30, 2016 and 73,697,371 shares at December 31, 2015 Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Cost of Goods Sold Cost of goods sold Cost of Sales [Member] Cost of Goods Sold Costs and Expenses Total costs and expenses Costs and Expenses [Abstract] Costs and expenses: Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Customer Relationships [Member] Customer relationships Debt, Current Short-term borrowings and current maturities of long-term debt Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Face Amount Debt instrument, aggregate principal amount Debt Instrument, Fair Value Disclosure Fair value of long-term debt including current maturities and the effects of the related interest rate swap contract Debt Instrument, Frequency of Periodic Payment Debt instrument, interest payment description Debt Instrument, Interest Rate, Stated Percentage Fixed-rate notes interest percentage Debt Instrument Maturity Year Debt Instrument Maturity Year Debt instrument, maturity year Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Term Line of credit facility, term, in years Debt Instrument, Unamortized Discount Debt instrument, debt issuance discount Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in unrecognized tax benefits within the next 12 months The fair value of shares purchased during the period under a deferred compensation arrangement. Deferred Compensation Arrangement With Individual Fair Value Of Shares Purchased Fair value per share of shares authorized for issuance Number of shares expected to be purchased by individuals pursuant to the terms of a deferred compensation arrangement. Deferred Compensation Arrangement With Individual Shares Anticipated Purchases Expected number of shares to be purchased in the period Number of shares purchased by individuals pursuant to the terms of a deferred compensation arrangement. Deferred Compensation Arrangement With Individual Shares Purchased Number of shares purchased in period Debt Issuance Cost, Gross, Noncurrent Debt instrument, debt offering costs Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Short-term deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax assets Deferred Tax Liabilities, Net, Noncurrent Deferred income taxes Defined Benefit Plan, Amortization of Gains (Losses) Amortization Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Return on Plan Assets Expected return on plan assets Defined Benefit Plan, Interest Cost Interest cost Defined Benefit Plan, Net Periodic Benefit Cost Net periodic pension cost Net Pension Periodic Cost Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period, net of employee contributions. The portion of the expected postretirement benefit obligation attributed to employee service during the period. Defined Benefit Plan Service Cost Net Of Employee Contributions Service cost, net of employee contributions Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Derivative Contract [Domain] Derivative Contract [Domain] Derivative Asset, Fair Value, Gross Asset Fair value of derivative assets Derivative Liability, Fair Value, Gross Liability Fair value of derivative liability Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net Gain/(Loss) Recognized in Other Comprehensive Income (Loss) Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion Derivative instruments, loss recorded in accumulated other comprehensive loss Derivative [Line Items] Derivative [Line Items] Derivative, Notional Amount Notional value of derivative contracts Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative [Table] Derivative [Table] Designated as Hedging Instrument [Member] Derivatives Designated as Hedging Instruments Directors Plan [Member] Directors Plan [Member] Directors Plan Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Compensation Plans Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Risk-adjusted discount rate used to determine fair value of in-process research and development assets acquired. Discount Rate for in Process Research and Development Valuation Risk-adjusted discount rate Document and Entity Information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic Basic earnings (loss) per share available to common shareholders Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted Diluted earnings (loss) per share available to common shareholders Earnings Per Share [Text Block] Earnings per Common Share Effective Income Tax Rate Reconciliation, Percent Effective income tax rate Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Embo Medical Limited [Member] Embo Medical Limited [Member] Embo Medical Limited Employee-related Liabilities, Current Accrued compensation and benefits Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation expenses related to share-based payment arrangements Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average period of recognizing unrecognized compensation expenses related to share-based compensation, in years Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Europe [Member] Europe Excess Tax Benefit from Share-based Compensation, Financing Activities Excess tax benefit relating to share-based compensation plans Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Federal Law Claims [Member] Federal Law Claims [Member] Federal Law Claims Filter Product Claims [Member] Filter Product Claims [Member] Filter Product Claims Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments Disclosure [Text Block] Financial Instruments Financial Instruments, Owned, at Fair Value Financial instrument assets and (liabilities) measured at fair value Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Core and developed technologies, net Finite-Lived Intangible Asset, Useful Life Estimated useful lives, years Five Year Credit Facility Expiring In November Two Thousand Twenty [Member] Five Year Credit Facility Expiring In November Two Thousand Twenty [Member] Five Year Credit Facility Expiring In November 2020 Foreign Exchange Contract [Member] Foreign Exchange Contract Foreign Exchange Forward [Member] Forward currency contracts Foreign Exchange Option [Member] Option currency contracts Forward Contracts [Member] Forward currency contracts Forward Starting Interest Rate Swaps [Member] Forward Starting Interest Rate Swaps [Member] Forward Starting Interest Rate Swaps Goodwill Goodwill Goodwill, Acquired During Period Purchase price allocation at fair value, goodwill Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Hedging Relationship [Domain] Hedging Relationship [Domain] Hernia Product Claims [Member] Hernia Product Claims [Member] Hernia Product Claims Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) from operations before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes EX-101.PRE 12 bcr-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2016 shares
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	BCR
Entity Registrant Name	BARD C R INC /NJ/
Entity Central Index Key	0000009892
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	73,526,324

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net sales	$ 941.9	$ 865.7	$ 2,746.9	$ 2,545.2
Costs and expenses:
Cost of goods sold	352.2	336.3	1,023.6	981.2
Marketing, selling and administrative expense	272.6	247.1	821.7	732.8
Research and development expense	74.2	65.2	213.8	189.8
Interest expense	14.9	11.2	39.6	33.7
Other (income) expense, net	115.8	258.3	185.4	416.3
Total costs and expenses	829.7	918.1	2,284.1	2,353.8
Income (loss) from operations before income taxes	112.2	(52.4)	462.8	191.4
Income tax provision	15.8	33.6	91.0	192.3
Net income (loss)	$ 96.4	$ (86.0)	$ 371.8	$ (0.9)
Basic earnings (loss) per share available to common shareholders	$ 1.30	$ (1.16)	$ 5.00	$ (0.01)
Diluted earnings (loss) per share available to common shareholders	$ 1.27	$ (1.16)	$ 4.92	$ (0.01)

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income (loss)	$ 96.4	$ (86.0)	$ 371.8	$ (0.9)
Other comprehensive income (loss)
Change in derivative instruments designated as cash flow hedges, net of tax	(0.4)	(15.4)	(15.9)	(11.5)
Foreign currency translation adjustments	(12.5)	3.2	8.2	(61.4)
Benefit plan adjustments, net of tax	1.7	2.0	5.1	5.8
Other comprehensive income (loss)	(11.2)	(10.2)	(2.6)	(67.1)
Comprehensive income (loss)	$ 85.2	$ (96.2)	$ 369.2	$ (68.0)

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 996.4	$ 950.5
Restricted cash	153.5	80.4
Accounts receivable, less allowances of $10,500 and $7,500, respectively	455.8	445.1
Inventories	487.7	413.7
Short-term deferred tax assets	116.1	123.9
Other current assets	92.9	79.6
Total current assets	2,302.4	2,093.2
Property, plant and equipment, at cost	866.9	807.8
Less accumulated depreciation and amortization	390.0	335.4
Net property, plant and equipment	476.9	472.4
Goodwill	1,268.8	1,140.6
Core and developed technologies, net	712.1	744.3
Other intangible assets, net	338.0	274.8
Deferred tax assets	20.8	21.8
Other assets	191.7	192.1
Total assets	5,310.7	4,939.2
Current liabilities
Short-term borrowings and current maturities of long-term debt	0.0	250.2
Accounts payable	95.7	70.7
Accrued expenses	588.2	730.0
Accrued compensation and benefits	170.3	187.9
Income taxes payable	20.9	23.0
Total current liabilities	875.1	1,261.8
Long-term debt	1,641.2	1,144.1
Other long-term liabilities	960.6	936.7
Deferred income taxes	111.7	141.3
Commitments and contingencies
Shareholders' investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 73,526,324 shares at September 30, 2016 and 73,697,371 shares at December 31, 2015	18.4	18.4
Capital in excess of par value	2,314.8	2,148.4
Accumulated deficit	(400.5)	(503.5)
Accumulated other comprehensive loss	(210.6)	(208.0)
Total shareholders' investment	1,722.1	1,455.3
Total liabilities and shareholders' investment	$ 5,310.7	$ 4,939.2

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Accounts receivable, allowances	$ 10.5	$ 7.5
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.25	$ 0.25
Common stock, authorized	600,000,000	600,000,000
Common stock, issued	73,526,324	73,697,371
Common stock, outstanding	73,526,324	73,697,371

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 371.8	$ (0.9)
Adjustments to reconcile net income to net cash provided by operating activities, net of acquired businesses:
Depreciation and amortization	160.7	143.0
Litigation charges, net	159.2	590.0
Restructuring and productivity initiative costs, net of payments	3.8	14.6
Asset impairment	1.2	0.0
Deferred income taxes	(42.8)	(32.8)
Share-based compensation	68.3	61.1
Inventory reserves and provision for doubtful accounts	23.3	16.3
Other items	2.1	3.9
Changes in assets and liabilities, net of acquired businesses:
Accounts receivable	10.3	5.1
Inventories	(78.7)	(38.5)
Current liabilities	(310.4)	(133.8)
Taxes	(19.5)	57.2
Other, net	(5.1)	(3.9)
Net cash provided by operating activities	344.2	681.3
Cash flows from investing activities:
Capital expenditures	(64.6)	(79.3)
Change in restricted cash	(73.1)	(14.2)
Payments made for purchases of businesses, net of cash acquired	(202.8)	(74.5)
Payments made for intangibles	(0.6)	(0.7)
Net cash used in investing activities	(341.1)	(168.7)
Cash flows from financing activities:
Change in short-term borrowings, net	0.0	(78.0)
Proceeds from issuance of long-term debt, net	495.6	0.0
Payment of long-term debt	(250.0)	(4.0)
Proceeds from exercises under share-based compensation plans, net	49.8	50.6
Excess tax benefit relating to share-based compensation plans	35.3	32.0
Purchases of common stock	(231.8)	(386.3)
Dividends paid	(55.3)	(51.6)
Payments of contingent consideration	(1.7)	(6.9)
Net cash provided by (used in) financing activities	41.9	(444.2)
Effect of exchange rate changes on cash and cash equivalents	0.9	(26.8)
Increase in cash and cash equivalents during the period	45.9	41.6
Balance at January 1	950.5	960.1
Balance at September 30	996.4	1,001.7
Cash paid for:
Interest	37.1	37.4
Income taxes	118.0	135.9
Non-cash transactions:
Purchases of businesses and related costs	$ 17.1	$ 5.7

XML 19 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2016

Basis of Presentation

1. Basis of Presentation

Recently Adopted Accounting Pronouncement

New Accounting Pronouncements Not Yet Adopted

XML 20 R8.htm IDEA: XBRL DOCUMENT

Acquisitions

9 Months Ended

Sep. 30, 2016

Acquisitions

2. Acquisitions

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Earnings per Common Share

9 Months Ended

Sep. 30, 2016

Earnings per Common Share

3. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:


	Quarter Ended September 30,					Nine Months Ended September 30,
	2016		2015			2016		2015
(dollars and shares in millions)
EPS Numerator:
Net income (loss)	$	96.4	$	(86.0	)	$	371.8	$	(0.9	)
Less: Income allocated to participating securities		0.4		—			1.8		—

Net income (loss) available to common shareholders	$	96.0	$	(86.0	)	$	370.0	$	(0.9	)

EPS Denominator:
Weighted average common shares outstanding		74.1		74.1			74.0		74.2
Dilutive common share equivalents from share-based compensation plans		1.2		—			1.2		—

Weighted average common and common equivalent shares outstanding, assuming dilution		75.3		74.1			75.2		74.2

XML 22 R10.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Taxes

4. Income Taxes

At September 30, 2016, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $21.8 million (of which $18.2 million would impact the effective tax rate, if recognized) plus $3.3 million of accrued interest. At December 31, 2015, the liability for unrecognized tax benefits was $22.3 million plus $2.8 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $3.0 million within the next 12 months.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Financial Instruments

9 Months Ended

Sep. 30, 2016

Financial Instruments

5. Financial Instruments

For further discussion regarding the company’s use of derivative instruments, see Note 1 of the notes to consolidated financial statements in Bard’s 2015 Annual Report on Form 10-K.

Foreign Exchange Derivative Instruments

Interest Rate Derivative Instruments

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:


	Balance Sheet Location		Fair Value of Derivatives
Derivatives Designated as Hedging Instruments	Balance Sheet Location		September 30, 2016		December 31, 2015
(dollars in millions)
Forward currency contracts		Other current assets	$	1.3	$	2.9
Option currency contracts		Other current assets		0.2		3.8
Interest rate swap contract		Other current assets		—		0.2
Forward currency contracts		Other assets		0.3		—

			$	1.8	$	6.9

Forward currency contracts		Accrued expenses	$	11.4	$	6.2
Interest rate swap contract		Accrued expenses		—		8.0
Forward currency contracts		Other long-term liabilities		2.5		—

			$	13.9	$	14.2

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Quarter Ended September 30,								Quarter Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(3.5	)	$	(3.6	)		Cost of goods sold	$	(1.2	)	$	(1.6	)
Option currency contracts		(0.3	)		(2.4	)		Cost of goods sold		(0.8	)		4.5
Interest rate swap contract		—			(12.9	)		Interest expense		(0.5	)		—

	$	(3.8	)	$	(18.9	)			$	(2.5	)	$	2.9


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Nine Months Ended September 30,								Nine Months Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(15.3	)	$	(5.4	)		Cost of goods sold	$	(5.9	)	$	(1.0	)
Option currency contracts		(3.3	)		8.0			Cost of goods sold		0.2			9.0
Interest rate swap contract		(15.3	)		(10.7	)		Interest expense		(0.9	)		—

	$	(33.9	)	$	(8.1	)			$	(6.6	)	$	8.0

Financial Instruments Measured at Fair Value on a Recurring Basis

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:


	September 30, 2016			December 31, 2015
(dollars in millions)
Forward currency contracts	$	(12.3	)	$	(3.3	)
Option currency contracts		0.2			3.8
Interest rate swap contracts		—			(7.8	)

Financial Instruments Not Measured at Fair Value

The company maintains a $1 billion five-year committed syndicated bank credit facility that expires in November 2020. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit ratings and includes a financial covenant that limits the amount of total debt to total capitalization. At September 30, 2016 the company was in compliance with this covenant. There were no commercial paper borrowings outstanding at September 30, 2016 or December 31, 2015.

Concentration Risk

XML 24 R12.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2016

Inventories

6. Inventories

Inventories consisted of:


	September 30, 2016		December 31, 2015
(dollars in millions)
Finished goods	$	293.3	$	252.3
Work in process		32.9		23.8
Raw materials		161.5		137.6

	$	487.7	$	413.7

XML 25 R13.htm IDEA: XBRL DOCUMENT

Contingencies

9 Months Ended

Sep. 30, 2016

Contingencies

7. Contingencies

Product Liability Matters

Hernia Product Claims

Women’s Health Product Claims

Filter Product Claims

General

Other Legal Matters

Litigation Reserves

In the first quarter of 2016, the company recorded an additional charge related to these matters to other (income) expense, net, of approximately $49 million ($31 million after tax). The company recorded this charge based on additional information obtained with respect to the quarter. Specifically, the company considered, among other factors, additional information learned regarding the nature and quantity of unfiled and filed claims, the increase in advertising by plaintiffs’ counsel with respect to IVC filters and an increase in the rate of claims being filed in Filter Product Claims (which led the company to increase its estimate of future Filter Product Claims).

XML 26 R14.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Plans

9 Months Ended

Sep. 30, 2016

Share-Based Compensation Plans

8. Share-Based Compensation Plans

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Pension Plans

9 Months Ended

Sep. 30, 2016

Pension Plans

9. Pension Plans

The components of net periodic pension cost are as follows:


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
(dollars in millions)
Service cost, net of employee contributions	$	7.5		$	7.1		$	22.0		$	22.1
Interest cost		4.8			5.2			14.2			15.1
Expected return on plan assets		(8.0	)		(7.9	)		(24.2	)		(23.5	)
Amortization		2.6			3.1			7.8			8.9

Net periodic pension cost	$	6.9		$	7.5		$	19.8		$	22.6

XML 28 R16.htm IDEA: XBRL DOCUMENT

Shareholders' Investment

9 Months Ended

Sep. 30, 2016

Shareholders' Investment

10. Shareholders’ Investment

The company repurchased approximately 1.2 million shares of common stock for $231.8 million in the nine months ended September 30, 2016 under its previously announced share repurchase authorizations.

Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss) by component are as follows:


	Derivative Instruments Designated as Cash Flow Hedges			Foreign Currency Translation Adjustments			Benefit Plans			Total
(dollars in millions)
Balance at December 31, 2014	$	0.9		$	(3.1	)	$	(86.6	)	$	(88.8	)
Other comprehensive income (loss) before reclassifications		(8.3	)		(61.4	)		—			(69.7	)
Tax (provision) benefit ^(a)		2.4			—			—			2.4

Other comprehensive income (loss) before reclassifications, net of taxes		(5.9	)		(61.4	)		—			(67.3	)

Reclassifications		(8.0	)^(b)		—			8.9	^(c)		0.9
Tax provision (benefit)		2.4			—			(3.1	)		(0.7	)

Reclassifications, net of tax		(5.6	)		—			5.8			0.2

Other comprehensive income (loss)		(11.5	)		(61.4	)		5.8			(67.1	)

Balance at September 30, 2015	$	(10.6	)	$	(64.5	)	$	(80.8	)	$	(155.9	)


Balance at December 31, 2015	$	(8.7	)	$	(94.2	)	$	(105.1	)	$	(208.0	)
Other comprehensive income (loss) before reclassifications		(31.1	)		8.2			—			(22.9	)
Tax (provision) benefit ^(a)		8.5			—			—			8.5

Other comprehensive income (loss) before reclassifications, net of taxes		(22.6	)		8.2			—			(14.4	)

Reclassifications		6.6	^(b)		—			7.8	^(c)		14.4
Tax provision (benefit)		0.1			—			(2.7	)		(2.6	)

Reclassifications, net of tax		6.7			—			5.1			11.8

Other comprehensive income (loss)		(15.9	)		8.2			5.1			(2.6	)

Balance at September 30, 2016	$	(24.6	)	$	(86.0	)	$	(100.0	)	$	(210.6	)

(a)	Income taxes are not provided for foreign currency translation adjustment.

(b)	See Note 5 of the notes to condensed consolidated financial statements.

(c)	These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Segment Information

9 Months Ended

Sep. 30, 2016

Segment Information

11. Segment Information

Net sales based on the location of external customers by geographic region are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
United States	$	646.0	$	606.5	$	1,904.5	$	1,772.6
Europe		108.6		107.4		328.6		322.6
Japan		60.1		41.6		150.5		125.8
Other		127.2		110.2		363.3		324.2

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

Total net sales by product group category are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
Vascular	$	258.1	$	250.5	$	752.9	$	731.0
Urology		242.1		212.3		698.8		627.1
Oncology		258.4		239.3		752.7		699.1
Surgical Specialties		158.8		139.8		470.1		419.5
Other		24.5		23.8		72.4		68.5

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Earnings per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share Computation

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:


	Quarter Ended September 30,					Nine Months Ended September 30,
	2016		2015			2016		2015
(dollars and shares in millions)
EPS Numerator:
Net income (loss)	$	96.4	$	(86.0	)	$	371.8	$	(0.9	)
Less: Income allocated to participating securities		0.4		—			1.8		—

Net income (loss) available to common shareholders	$	96.0	$	(86.0	)	$	370.0	$	(0.9	)

EPS Denominator:
Weighted average common shares outstanding		74.1		74.1			74.0		74.2
Dilutive common share equivalents from share-based compensation plans		1.2		—			1.2		—

Weighted average common and common equivalent shares outstanding, assuming dilution		75.3		74.1			75.2		74.2

XML 31 R19.htm IDEA: XBRL DOCUMENT

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Location and Fair Value of Derivative Instruments Designated as Hedging Instruments

The location and fair value of derivative instruments that are designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:


	Balance Sheet Location		Fair Value of Derivatives
Derivatives Designated as Hedging Instruments	Balance Sheet Location		September 30, 2016		December 31, 2015
(dollars in millions)
Forward currency contracts		Other current assets	$	1.3	$	2.9
Option currency contracts		Other current assets		0.2		3.8
Interest rate swap contract		Other current assets		—		0.2
Forward currency contracts		Other assets		0.3		—

			$	1.8	$	6.9

Forward currency contracts		Accrued expenses	$	11.4	$	6.2
Interest rate swap contract		Accrued expenses		—		8.0
Forward currency contracts		Other long-term liabilities		2.5		—

			$	13.9	$	14.2

Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Quarter Ended September 30,								Quarter Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(3.5	)	$	(3.6	)		Cost of goods sold	$	(1.2	)	$	(1.6	)
Option currency contracts		(0.3	)		(2.4	)		Cost of goods sold		(0.8	)		4.5
Interest rate swap contract		—			(12.9	)		Interest expense		(0.5	)		—

	$	(3.8	)	$	(18.9	)			$	(2.5	)	$	2.9


	Gain/(Loss) Recognized in Other Comprehensive Income (Loss)						Location of Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income		Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income
	Nine Months Ended September 30,								Nine Months Ended September 30,
	2016			2015					2016			2015
(dollars in millions)
Forward currency contracts	$	(15.3	)	$	(5.4	)		Cost of goods sold	$	(5.9	)	$	(1.0	)
Option currency contracts		(3.3	)		8.0			Cost of goods sold		0.2			9.0
Interest rate swap contract		(15.3	)		(10.7	)		Interest expense		(0.9	)		—

	$	(33.9	)	$	(8.1	)			$	(6.6	)	$	8.0

Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:


	September 30, 2016			December 31, 2015
(dollars in millions)
Forward currency contracts	$	(12.3	)	$	(3.3	)
Option currency contracts		0.2			3.8
Interest rate swap contracts		—			(7.8	)

XML 32 R20.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventories

Inventories consisted of:


	September 30, 2016		December 31, 2015
(dollars in millions)
Finished goods	$	293.3	$	252.3
Work in process		32.9		23.8
Raw materials		161.5		137.6

	$	487.7	$	413.7

XML 33 R21.htm IDEA: XBRL DOCUMENT

Pension Plans (Tables)

9 Months Ended

Sep. 30, 2016

Components of Net Periodic Pension Cost

The components of net periodic pension cost are as follows:


	Quarter Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
(dollars in millions)
Service cost, net of employee contributions	$	7.5		$	7.1		$	22.0		$	22.1
Interest cost		4.8			5.2			14.2			15.1
Expected return on plan assets		(8.0	)		(7.9	)		(24.2	)		(23.5	)
Amortization		2.6			3.1			7.8			8.9

Net periodic pension cost	$	6.9		$	7.5		$	19.8		$	22.6

XML 34 R22.htm IDEA: XBRL DOCUMENT

Shareholders' Investment (Tables)

9 Months Ended

Sep. 30, 2016

Changes in Accumulated Other Comprehensive Income (Loss) by Component

The changes in accumulated other comprehensive income (loss) by component are as follows:


	Derivative Instruments Designated as Cash Flow Hedges			Foreign Currency Translation Adjustments			Benefit Plans			Total
(dollars in millions)
Balance at December 31, 2014	$	0.9		$	(3.1	)	$	(86.6	)	$	(88.8	)
Other comprehensive income (loss) before reclassifications		(8.3	)		(61.4	)		—			(69.7	)
Tax (provision) benefit ^(a)		2.4			—			—			2.4

Other comprehensive income (loss) before reclassifications, net of taxes		(5.9	)		(61.4	)		—			(67.3	)

Reclassifications		(8.0	)^(b)		—			8.9	^(c)		0.9
Tax provision (benefit)		2.4			—			(3.1	)		(0.7	)

Reclassifications, net of tax		(5.6	)		—			5.8			0.2

Other comprehensive income (loss)		(11.5	)		(61.4	)		5.8			(67.1	)

Balance at September 30, 2015	$	(10.6	)	$	(64.5	)	$	(80.8	)	$	(155.9	)


Balance at December 31, 2015	$	(8.7	)	$	(94.2	)	$	(105.1	)	$	(208.0	)
Other comprehensive income (loss) before reclassifications		(31.1	)		8.2			—			(22.9	)
Tax (provision) benefit ^(a)		8.5			—			—			8.5

Other comprehensive income (loss) before reclassifications, net of taxes		(22.6	)		8.2			—			(14.4	)

Reclassifications		6.6	^(b)		—			7.8	^(c)		14.4
Tax provision (benefit)		0.1			—			(2.7	)		(2.6	)

Reclassifications, net of tax		6.7			—			5.1			11.8

Other comprehensive income (loss)		(15.9	)		8.2			5.1			(2.6	)

Balance at September 30, 2016	$	(24.6	)	$	(86.0	)	$	(100.0	)	$	(210.6	)

(a)	Income taxes are not provided for foreign currency translation adjustment.

(b)	See Note 5 of the notes to condensed consolidated financial statements.

(c)	These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

9 Months Ended

Sep. 30, 2016

Net Sales Based on the Location of External Customers by Geographic Region

Net sales based on the location of external customers by geographic region are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
United States	$	646.0	$	606.5	$	1,904.5	$	1,772.6
Europe		108.6		107.4		328.6		322.6
Japan		60.1		41.6		150.5		125.8
Other		127.2		110.2		363.3		324.2

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

Total Net Sales by Product Group Category

Total net sales by product group category are:


	Quarter Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
(dollars in millions)
Vascular	$	258.1	$	250.5	$	752.9	$	731.0
Urology		242.1		212.3		698.8		627.1
Oncology		258.4		239.3		752.7		699.1
Surgical Specialties		158.8		139.8		470.1		419.5
Other		24.5		23.8		72.4		68.5

	$	941.9	$	865.7	$	2,746.9	$	2,545.2

XML 36 R24.htm IDEA: XBRL DOCUMENT

Acquisitions - Additional Information (Detail) - USD ($) $ in Millions	Jan. 21, 2016	Dec. 03, 2015
Liberator Medical Holdings, Inc.
Business Acquisitions and Dispositions [Line Items]
Percentage of outstanding stock acquired	100.00%
Business acquisition, purchase consideration cash payment	$ 181.1
Purchase price allocation at fair value, recognition of deferred tax liabilities	31.6
Business Combination, recognized identifiable assets acquired and liabilities assumed, other net assets and liabilities	11.9
Purchase price allocation at fair value, goodwill	121.8
Embo Medical Limited
Business Acquisitions and Dispositions [Line Items]
Percentage of outstanding stock acquired		100.00%
Business acquisition, purchase consideration cash payment		$ 21.0
Business Combination, recognized identifiable assets acquired and liabilities assumed, other net assets and liabilities		(2.9)
Purchase price allocation at fair value, goodwill		4.4
Business acquisition, maximum contingent consideration		22.5
Business combination, contingent consideration, liability		16.6
Customer relationships \| Liberator Medical Holdings, Inc.
Business Acquisitions and Dispositions [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset	$ 53.0
Customer relationships \| Weighted Average \| Liberator Medical Holdings, Inc.
Business Acquisitions and Dispositions [Line Items]
Estimated useful lives, years	12 years
Other Intangible Assets \| Liberator Medical Holdings, Inc.
Business Acquisitions and Dispositions [Line Items]
Purchase price allocation at fair value, recognition of finite-lived intangible asset	$ 26.0
Other Intangible Assets \| Weighted Average \| Liberator Medical Holdings, Inc.
Business Acquisitions and Dispositions [Line Items]
Estimated useful lives, years	8 years
In-Process Research And Development \| Embo Medical Limited
Business Acquisitions and Dispositions [Line Items]
Purchase price allocation at fair value, recognition of indefinite-lived intangible asset		$ 36.1
Risk-adjusted discount rate		17.50%

XML 37 R25.htm IDEA: XBRL DOCUMENT

Earnings Per Share Computation (Detail) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss)	$ 96.4	$ (86.0)	$ 371.8	$ (0.9)
Less: Income allocated to participating securities	0.4	0.0	1.8	0.0
Net income (loss) available to common shareholders	$ 96.0	$ (86.0)	$ 370.0	$ (0.9)
Weighted average common shares outstanding	74.1	74.1	74.0	74.2
Dilutive common share equivalents from share-based compensation plans	1.2	0.0	1.2	0.0
Weighted average common and common equivalent shares outstanding, assuming dilution	75.3	74.1	75.2	74.2

XML 38 R26.htm IDEA: XBRL DOCUMENT

Earnings per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents not included in computation of diluted weighted average shares outstanding	1.3	1.3

XML 39 R27.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Income Tax [Line Items]
Effective income tax rate	14.10%	19.70%
Income tax examination, increase (decrease) in liability from prior year	$ 2.6	$ 2.6
Unrecognized tax benefits related to federal, state and foreign taxes	21.8	21.8	$ 22.3
Unrecognized tax benefits that would impact effective tax rate	18.2	18.2
Accrued interest	3.3	3.3	$ 2.8
Decrease in unrecognized tax benefits within the next 12 months	$ 3.0	$ 3.0
Number of months unrecognized tax benefits may decrease		12 months

XML 40 R28.htm IDEA: XBRL DOCUMENT

Financial Instruments - Additional Information (Detail)		1 Months Ended	9 Months Ended
Financial Instruments - Additional Information (Detail)	May 09, 2016 USD ($)	May 31, 2016 USD ($)	Sep. 30, 2016 USD ($) Country	Sep. 30, 2015 USD ($)	Jan. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Derivative [Line Items]
Debt instrument, net proceeds from offering			$ 495,600,000	$ 0
3.000% senior unsecured notes due 2026
Derivative [Line Items]
Fixed-rate notes interest percentage	3.00%
Debt instrument, maturity year	2026
Debt instrument, aggregate principal amount	$ 500,000,000
Debt instrument, interest payment description			Semi-annually
Debt instrument, net proceeds from offering	495,600,000
Debt instrument, debt offering costs	4,300,000
Debt instrument, debt issuance discount	$ 100,000
Five Year Credit Facility Expiring In November 2020
Derivative [Line Items]
Line of credit facility, borrowing capacity			$ 1,000,000,000
Line of credit facility, expiration date			2020-11
Line of credit facility, term, in years			5 years
Commercial Paper
Derivative [Line Items]
Commercial paper borrowings outstanding			$ 0			$ 0
National Healthcare Systems and Private Sector Customers \| Spain, Italy, Greece, and Portugal
Derivative [Line Items]
Accounts receivable, net			45,900,000
Accounts receivable greater than 365 days past due			$ 4,200,000
The number of countries in Europe in which certain collection risks exist \| Country			4
Medicon Inc \| Other Long-term Liabilities
Derivative [Line Items]
Liability for non-continent future payments for business combinations			$ 60,300,000			50,300,000
Fair Value, Inputs, Level 3 \| Fair Value, Measurements, Recurring
Derivative [Line Items]
Fair value of contingent consideration			19,700,000			11,200,000
Fair Value, Inputs, Level 2
Derivative [Line Items]
Fair value of long-term debt including current maturities and the effects of the related interest rate swap contract			1,748,700,000			1,449,800,000
Fair Value, Inputs, Level 2 \| Medicon Inc
Derivative [Line Items]
Liability for non-continent future payments for business combinations			79,100,000			66,000,000
Interest rate swap contract
Derivative [Line Items]
Notional value of derivative contracts					$ 250,000,000
Fixed-rate notes interest percentage					2.875%
Foreign Exchange Contract
Derivative [Line Items]
Notional value of derivative contracts			$ 321,400,000			$ 191,600,000
Forward Starting Interest Rate Swaps
Derivative [Line Items]
Notional value of derivative contracts		$ 250,000,000
Derivative instruments, loss recorded in accumulated other comprehensive loss		$ 23,300,000
Forward Starting Interest Rate Swaps \| 3.000% senior unsecured notes due 2026
Derivative [Line Items]
Fixed-rate notes interest percentage	3.00%
Debt instrument, maturity year	2026

XML 41 R29.htm IDEA: XBRL DOCUMENT

Location and Fair Value of Derivative Instruments Designated as Hedging Instruments (Detail) - Derivatives Designated as Hedging Instruments - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	$ 1.8	$ 6.9
Fair value of derivative liability	13.9	14.2
Forward currency contracts \| Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	1.3	2.9
Forward currency contracts \| Other Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0.3	0.0
Forward currency contracts \| Accrued Expenses
Derivatives, Fair Value [Line Items]
Fair value of derivative liability	11.4	6.2
Forward currency contracts \| Other Long-term Liabilities
Derivatives, Fair Value [Line Items]
Fair value of derivative liability	2.5	0.0
Option currency contracts \| Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0.2	3.8
Interest rate swap contract \| Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0.0	0.2
Interest rate swap contract \| Accrued Expenses
Derivatives, Fair Value [Line Items]
Fair value of derivative liability	$ 0.0	$ 8.0

XML 42 R30.htm IDEA: XBRL DOCUMENT

Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) - Cash flow hedges - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income (Loss)	$ (3.8)	$ (18.9)	$ (33.9)	$ (8.1)
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income	(2.5)	2.9	(6.6)	8.0
Forward currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income (Loss)	(3.5)	(3.6)	(15.3)	(5.4)
Forward currency contracts \| Cost of Goods Sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income	(1.2)	(1.6)	(5.9)	(1.0)
Option currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income (Loss)	(0.3)	(2.4)	(3.3)	8.0
Option currency contracts \| Cost of Goods Sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income	(0.8)	4.5	0.2	9.0
Interest rate swap contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income (Loss)	0.0	(12.9)	(15.3)	(10.7)
Interest rate swap contract \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified from Accumulated Other Comprehensive Loss into Income	$ (0.5)	$ 0.0	$ (0.9)	$ 0.0

XML 43 R31.htm IDEA: XBRL DOCUMENT

Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - Fair Value, Inputs, Level 2 - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Forward currency contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	$ (12.3)	$ (3.3)
Option currency contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	0.2	3.8
Interest rate swap contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	$ 0.0	$ (7.8)

XML 44 R32.htm IDEA: XBRL DOCUMENT

Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Finished goods	$ 293.3	$ 252.3
Work in process	32.9	23.8
Raw materials	161.5	137.6
Inventory, net, total	$ 487.7	$ 413.7

XML 45 R33.htm IDEA: XBRL DOCUMENT

Contingencies - Additional Information (Detail) $ in Millions		1 Months Ended					3 Months Ended					9 Months Ended		12 Months Ended		69 Months Ended
	Sep. 30, 2016 USD ($) LegalMatter Subsidiary Plaintiff Claim Trial Proceeding	Apr. 30, 2015 LegalMatter	Apr. 30, 2014 LegalMatter	Jul. 31, 2013 USD ($)	Jul. 31, 2012 USD ($)	Jun. 30, 2007 LegalMatter	Sep. 30, 2016 USD ($) LegalMatter	Mar. 31, 2016 USD ($)	Sep. 30, 2015 USD ($) LegalMatter	Jun. 30, 2015 USD ($) LegalMatter	Jun. 30, 2014 USD ($)	Sep. 30, 2016 USD ($) LegalMatter	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) LegalMatter	Dec. 31, 2014 LegalMatter	Sep. 30, 2016 USD ($) LegalMatter	Jul. 31, 2014 LegalMatter	Jan. 16, 2014 LegalMatter
Commitments and Contingencies [Line Items]
Product claims, charges incurred after tax \| $							$ 77.0	$ 31.0	$ 228.0	$ 325.0	$ 238.0
Accruals for product liability and other legal matters \| $	$ 1,066.4						1,066.4					$ 1,066.4		$ 1,174.3		$ 1,066.4
Payments to qualified settlement fund \| $												289.3				676.5
Payments to qualified claimants from qualified settlement funds \| $												216.1				524.8
Other payments to qualified claimants from qualified settlement funds \| $												9.1				71.6
Minimum
Commitments and Contingencies [Line Items]
Proceedings that could be material to the company \| Proceeding	1
Cases that could be settled at any time \| Claim	1
Accrued Expenses
Commitments and Contingencies [Line Items]
Accruals for product liability and other legal matters, accrued expenses \| $	$ 404.3						404.3					404.3		516.5		404.3
Receivables Related to Product Liability Matters
Commitments and Contingencies [Line Items]
Receivables related to product liability matters \| $	135.4						135.4					135.4		132.8		135.4
Receivables Related to Product Liability Matters \| Other Assets
Commitments and Contingencies [Line Items]
Receivables related to product liability matters, noncurrent \| $	$ 135.4						135.4					$ 135.4		$ 132.1		$ 135.4
Other (income) expense, net
Commitments and Contingencies [Line Items]
Product claims, charges incurred before taxes \| $							$ 111.0	$ 49.0	$ 241.0	$ 337.0	$ 259.0
Hernia Product Claims
Commitments and Contingencies [Line Items]
Number of individual plaintiffs \| Plaintiff	105
Period for additional product claims trials	12 months
Hernia Product Claims \| United States
Commitments and Contingencies [Line Items]
Number of putative class actions	1
Hernia Product Claims \| Canada
Commitments and Contingencies [Line Items]
Number of putative class actions settled			3
Hernia Product Claims \| Federal Law Claims
Commitments and Contingencies [Line Items]
Number of lawsuits	30						30					30				30
Hernia Product Claims \| State Law Claims
Commitments and Contingencies [Line Items]
Number of lawsuits	80						80					80				80
Hernia Product Claims \| State Law Claims \| Superior Court of State of Rhode Island
Commitments and Contingencies [Line Items]
Number of lawsuits	60						60					60				60
Number of individual plaintiffs \| Plaintiff	60
Number of multidistrict litigations						1
Women's Health Product Claims
Commitments and Contingencies [Line Items]
Number of individual plaintiffs \| Plaintiff	10,110
Period for additional product claims trials	12 months
Number of claims in settlement agreement	9,860											3,015		6,285	560
Generic complaints \| Claim	655
Number of claims not yet filed	980
The number of claims subject to an agreement or an agreement in principle									3,030	2,880
Women's Health Product Claims \| Minimum
Commitments and Contingencies [Line Items]
Number of additional trials \| Trial	1
Women's Health Product Claims \| California state case
Commitments and Contingencies [Line Items]
U. S. District Court award for plaintiff's damages \| $					$ 3.6
Women's Health Product Claims \| United States
Commitments and Contingencies [Line Items]
Number of putative class actions	5
Women's Health Product Claims \| Canada
Commitments and Contingencies [Line Items]
Number of putative class actions	5
Class actions settled												In March 2016, the company reached an agreement in principle to resolve all Canadian putative class actions, with the exception of a Quebec class action, within amounts previously recorded by the company.
Women's Health Product Claims \| Medtronic
Commitments and Contingencies [Line Items]
Number of subsidiaries of a parent company that have an obligation to indemnify \| Subsidiary	2
Women's Health Product Claims \| Medtronic
Commitments and Contingencies [Line Items]
Total payments made for settlement of indemnification obligation \| $													$ 121.0
Women's Health Product Claims \| Multi District Litigation
Commitments and Contingencies [Line Items]
U. S. District Court award for plaintiff's damages \| $				$ 2.0
Number of individual case for trial																	300	200
Women's Health Product Claims \| Ontario Superior Court of Justice \| Canada
Commitments and Contingencies [Line Items]
Number of putative class actions with class certifications dismissed		1
Filter Product Claims
Commitments and Contingencies [Line Items]
Number of individual plaintiffs \| Plaintiff	1,055
Number of multidistrict litigations	1
Period for additional product claims trials	12 months
Number of claims not yet filed	40
Filter Product Claims \| Canada
Commitments and Contingencies [Line Items]
Number of putative class actions	3
Filter Product Claims \| Multi District Litigation
Commitments and Contingencies [Line Items]
Number of lawsuits	1,005						1,005					1,005				1,005
Filter Product Claims \| State Law Claims
Commitments and Contingencies [Line Items]
Number of lawsuits	50						50					50				50

XML 46 R34.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Plans - Additional Information (Detail) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended				9 Months Ended
	Jul. 31, 2016 $ / shares shares	Jul. 31, 2015 $ / shares shares	Sep. 30, 2016 USD ($) shares	Mar. 31, 2016	Sep. 30, 2015 USD ($)	Mar. 31, 2015	Sep. 30, 2016 USD ($) CompensationPlan shares	Sep. 30, 2015 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of employee stock purchase programs \| CompensationPlan							2
Share-based payment arrangements \| $			$ 19.0		$ 17.0		$ 68.3	$ 61.1
Unrecognized compensation expenses related to share-based payment arrangements \| $			$ 109.9				$ 109.9
Weighted-average period of recognizing unrecognized compensation expenses related to share-based compensation, in years							2 years
Performance Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value assumptions, risk-free interest rate				0.83%		0.86%
Fair value assumptions, dividend yield				0.52%		0.51%
Fair value assumptions, expected life in years				2 years 10 months 21 days		2 years 9 months 11 days
Awards requisite service period				3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award							In the first quarter of each of 2016 and 2015, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights.
Period over which the company's performance is evaluated				3 years
2012 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of remaining shares that may be issued			4,670,191				4,670,191
Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of remaining shares that may be issued			26,102				26,102
Management Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value assumptions, risk-free interest rate	0.39%	0.16%
Fair value assumptions, dividend yield	0.50%	0.60%
Fair value assumptions, expected life in years	7 months 6 days	7 months 6 days
Expected number of shares to be purchased in the period	100,000
Number of shares purchased in period		200,000
Fair value per share of shares authorized for issuance \| $ / shares	$ 83.23	$ 60.47
Fair value assumptions, expected volatility	18.00%	17.00%

XML 47 R35.htm IDEA: XBRL DOCUMENT

Components of Net Periodic Pension Cost (Detail) - Pension Plans, Defined Benefit - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost, net of employee contributions	$ 7.5	$ 7.1	$ 22.0	$ 22.1
Interest cost	4.8	5.2	14.2	15.1
Expected return on plan assets	(8.0)	(7.9)	(24.2)	(23.5)
Amortization	2.6	3.1	7.8	8.9
Net periodic pension cost	$ 6.9	$ 7.5	$ 19.8	$ 22.6

XML 48 R36.htm IDEA: XBRL DOCUMENT

Pension Plans - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Change in Assumptions for Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Net Pension Periodic Cost	$ 1.2	$ 3.8

XML 49 R37.htm IDEA: XBRL DOCUMENT

Shareholders' Investment - Additional Information (Detail) shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2016 USD ($) shares
Shareholders Equity [Line Items]
Number of shares of common stock purchased \| shares	1.2
Purchase of common stock \| $	$ 231.8

XML 50 R38.htm IDEA: XBRL DOCUMENT

Changes in Accumulated Other Comprehensive Income (Loss) by Component (Detail) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Accumulated Other Comprehensive Income (Loss) [Line Items]

Beginning balance

$ 1,455.3

Other comprehensive income (loss) before reclassifications

(22.9)

$ (69.7)

Tax (provision) benefit

^[1]

8.5

2.4

Other comprehensive income (loss) before reclassifications, net of taxes

(14.4)

(67.3)

Reclassifications

14.4

0.9

Tax provision (benefit)

(2.6)

(0.7)

Reclassifications, net of tax

11.8

0.2

Other comprehensive income (loss)

$ (11.2)

$ (10.2)

(2.6)

(67.1)

Ending balance

1,722.1

Derivative Instruments Designated as Cash Flow Hedges

Accumulated Other Comprehensive Income (Loss) [Line Items]

Beginning balance

(8.7)

0.9

Other comprehensive income (loss) before reclassifications

(31.1)

(8.3)

Tax (provision) benefit

^[1]

8.5

2.4

Other comprehensive income (loss) before reclassifications, net of taxes

(22.6)

(5.9)

Reclassifications

^[2]

6.6

(8.0)

Tax provision (benefit)

0.1

2.4

Reclassifications, net of tax

6.7

(5.6)

Other comprehensive income (loss)

(15.9)

(11.5)

Ending balance

(24.6)

(10.6)

(24.6)

(10.6)

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss) [Line Items]

Beginning balance

(94.2)

(3.1)

Other comprehensive income (loss) before reclassifications

8.2

(61.4)

Tax (provision) benefit

^[1]

0.0

Other comprehensive income (loss) before reclassifications, net of taxes

8.2

(61.4)

Reclassifications

0.0

Tax provision (benefit)

0.0

Reclassifications, net of tax

0.0

Other comprehensive income (loss)

8.2

(61.4)

Ending balance

(86.0)

(64.5)

(86.0)

(64.5)

Benefit Plans

Accumulated Other Comprehensive Income (Loss) [Line Items]

Beginning balance

(105.1)

(86.6)

Other comprehensive income (loss) before reclassifications

0.0

Tax (provision) benefit

^[1]

0.0

Other comprehensive income (loss) before reclassifications, net of taxes

0.0

Reclassifications

^[3]

7.8

8.9

Tax provision (benefit)

(2.7)

(3.1)

Reclassifications, net of tax

5.1

5.8

Other comprehensive income (loss)

5.1

5.8

Ending balance

(100.0)

(80.8)

(100.0)

(80.8)

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Income (Loss) [Line Items]

Beginning balance

(208.0)

(88.8)

Ending balance

$ (210.6)

$ (155.9)

$ (210.6)

$ (155.9)

[1]	Income taxes are not provided for foreign currency translation adjustment.
[2]	See Note 5 of the notes to condensed consolidated financial statements.
[3]	These components are included in the computation of net periodic pension cost. See Note 9 of the notes to condensed consolidated financial statements.

XML 51 R39.htm IDEA: XBRL DOCUMENT

Net Sales Based on Location of External Customer and Identifiable Assets by Geographic Region (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net sales	$ 941.9	$ 865.7	$ 2,746.9	$ 2,545.2
United States
Segment Reporting Information [Line Items]
Net sales	646.0	606.5	1,904.5	1,772.6
Europe
Segment Reporting Information [Line Items]
Net sales	108.6	107.4	328.6	322.6
Japan
Segment Reporting Information [Line Items]
Net sales	60.1	41.6	150.5	125.8
Other
Segment Reporting Information [Line Items]
Net sales	$ 127.2	$ 110.2	$ 363.3	$ 324.2

XML 52 R40.htm IDEA: XBRL DOCUMENT

Total Net Sales by Product Group Category (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Net sales	$ 941.9	$ 865.7	$ 2,746.9	$ 2,545.2
Vascular
Segment Reporting Information [Line Items]
Net sales	258.1	250.5	752.9	731.0
Urology
Segment Reporting Information [Line Items]
Net sales	242.1	212.3	698.8	627.1
Oncology
Segment Reporting Information [Line Items]
Net sales	258.4	239.3	752.7	699.1
Surgical Specialties
Segment Reporting Information [Line Items]
Net sales	158.8	139.8	470.1	419.5
Other Product Group
Segment Reporting Information [Line Items]
Net sales	$ 24.5	$ 23.8	$ 72.4	$ 68.5

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if smaller reporting company)

Smaller reporting company